Method and apparatus for peptide production
The use of tag protecting groups in a flow reactor facilitates continuous peptide production by enabling two-phase separation and eliminating intermediate purification, reducing production time and steps.
Patent Information
- Application Number
- JP2023075533
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-01
- Publication Date
- 2024-11-14
AI Technical Summary
Existing peptide production methods using flow reactors require batch processing for separation and purification after each condensation and deprotection reaction, leading to prolonged production times.
A method utilizing a tag protecting group for C-terminal protection allows for two-phase separation and purification, enabling continuous deprotection of the N-terminal protecting group without intermediate purification steps, using a flow reactor to produce peptides in a shorter time.
Peptides can be produced in a reduced number of steps and in a significantly shorter time frame by employing a flow reactor with tag protecting groups for continuous processing.
Smart Images

Figure 2024160485000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to a method and an apparatus for producing a peptide. In particular, the present invention relates to a method and an apparatus for continuously producing a peptide using a flow reactor. [Background technology]
[0002] Peptides are widely used as ingredients in medicines and foods. Research and development of peptide synthesis has been carried out for over 100 years. Currently, liquid phase and solid phase methods are commonly used.
[0003] In the solid-phase method, the C-terminus of an amino acid or peptide is usually bound to a solid support, and the peptide chain is elongated on the N-terminus side. In the case of the solid-phase method, unreacted raw materials, reactants, and by-products can be easily removed by washing the solid support. On the other hand, the solid-phase method has low reactivity because the elongation reaction is carried out on the solid support, and as a result, it takes time to produce a peptide.
[0004] In the liquid phase method, the peptide chain elongation reaction is carried out in a reaction solution containing raw materials and reactants, and therefore the reactivity is high and the production scale can be easily adjusted. However, in the liquid phase method, the separation and purification of the products are carried out in a discontinuous process (batch process) for each condensation reaction and deprotection reaction, which makes the production process complicated and results in a long time required for peptide production.
[0005] A flow synthesis method using a flow reactor has been developed as a method for continuously carrying out condensation and deprotection reactions in a liquid phase method. The flow synthesis method uses a fine channel with an inner diameter of several mm or less as a reaction field (flow reactor). In the case of the flow synthesis method, the reaction solution can be mixed instantly, so the reaction time can be strictly controlled in units of several seconds. In addition, in the case of the flow synthesis method, the specific surface area per unit volume of the reaction solution is significantly larger than in the liquid phase method of ordinary batch processing, so the reaction system can be heated or cooled instantly. Due to these characteristics, the flow synthesis method can reduce the time and energy costs required for peptide production (Non-Patent Documents 1 and 2).
[0006] Although the flow synthesis method can reduce the time and energy costs required for the peptide chain elongation reaction, it is necessary to separate and purify the product in a batch process for each condensation reaction and deprotection reaction, as with the liquid phase method. In response to this problem in the liquid phase method and the flow synthesis method, a protecting group (hereinafter also referred to as a "pseudo solid phase protecting group" or "tag protecting group") has been developed that allows the separation and purification of the product by two-phase separation of an organic phase and an aqueous phase without the need for solid-liquid separation as in the solid phase method.
[0007] For example, US Pat. No. 5,399,633 describes benzyl compounds that can be used as such protecting groups.
[0008] Patent Document 2 describes a method for producing peptides using a flow reactor and a pseudo solid-phase protecting group. [Prior art documents] [Patent documents]
[0009] [Patent Document 1] International Publication No. 2017 / 038650 [Patent Document 2] International Publication No. 2020 / 218497 [Non-patent literature]
[0010] [Non-Patent Document 1] Otake, Y. et al., Angew. Chem. Int. Ed., 2020, Vol. 59, p. 12925-12930 [Non-Patent Document 2] Fuse, S. et al., Nature Communications, 2016, Vol. 7, p. 13491 Summary of the Invention [Problem to be solved by the invention]
[0011] As described above, a method for producing a peptide using a flow reactor has been developed. However, the conventional methods have some problems. For example, in the methods described in Non-Patent Documents 1 and 2, the separation and purification of the product for each condensation reaction and deprotection reaction must be performed in a batch process. Therefore, there is a problem that it takes a long time to produce a peptide as a whole.
[0012] Therefore, an object of the present invention is to provide a means for producing a peptide with fewer steps and in a short period of time. [Means for solving the problem]
[0013] The present inventors have investigated various means for solving the above problems. The present inventors have found that in a peptide production method using a flow reactor, by using a tag protecting group as a C-terminal protecting group, which allows the product to be separated and purified by two-phase separation of an organic phase and an aqueous phase, the N-terminal protecting group can be continuously deprotected without purifying the peptide after the condensation reaction, and the peptide can be produced in a short time. Based on the above findings, the present inventors have completed the present invention.
[0014] That is, the present invention includes the following aspects and embodiments. (Embodiment 1) a C-terminal activation step of introducing an N-terminal protected amino acid or peptide, the N-terminal amino group of which is protected by an N-terminal protecting group, and a C-terminal activating agent into a flow reactor, and activating the C-terminal carboxyl group of the N-terminal protected amino acid or peptide in the flow reactor to form a C-terminal activated derivative of the N-terminal protected amino acid or peptide; a condensation step in which a C-terminal activated derivative of the N-terminal protected amino acid or peptide and a C-terminal protected amino acid or peptide in which the C-terminal carboxyl group is protected by a tag protecting group are introduced into a flow reactor, and the N-terminal protected amino acid or peptide is condensed to the N-terminal side of the C-terminal protected amino acid or peptide in the flow reactor to form an N-terminal and C-terminal protected peptide extended to the N-terminal side; an N-terminal deprotection step in which the N-terminal and C-terminal protected peptide extended on the N-terminal side and a deprotecting agent for the N-terminal protecting group are introduced into a flow reactor, and the N-terminal protecting group is deprotected in the flow reactor to form a C-terminal protected peptide extended on the N-terminal side; and an extraction step in which the reaction mixture containing the N-terminally extended C-terminally protected peptide is mixed with an aqueous phase to extract the N-terminally extended C-terminally protected peptide into an organic phase; A method for producing a peptide, comprising: (Embodiment 2) 2. The method of embodiment 1, wherein the C-terminal activating agent is selected from the group consisting of halogenated ethyl formates, halogenated isopropyl formates, halogenated isobutyl formates, carboxylic acid halides, phosgene and phosgene equivalents, carbodiimide-based condensing agents, phosphonium-based condensing agents, uronium-based condensing agents, haluronium-based condensing agents, imidazole-based condensing agents, triazine-based condensing agents, and condensation additives. (Embodiment 3) The tag protecting group is (i) Formula (I): [ka] [In the formula, ring A represents an aromatic ring; Y represents a hydroxyl group, a bromo group, or a chloro group; Ra, Rb, and Rc each independently represent an organic group having an aliphatic hydrocarbon group, a hydrogen atom, or an electron-withdrawing group, and at least one of Ra, Rb, and Rc is an organic group having an aliphatic hydrocarbon group; rings A, B, and C each independently may have an electron-withdrawing group; Here, the organic group having an aliphatic hydrocarbon group is Formula (b): [ka] (In the formula, * indicates bond position; X 1 is -O-;R 1 is an aliphatic hydrocarbon group having 5 to 60 carbon atoms; m 1 is 1) A group represented by Formula (c): [ka] (In the formula, * indicates bond position; X 2 , X 2 ', X 2 '' and X 2 ''' is -O-;R 2 and R 4 are each independently an aliphatic hydrocarbon group having 5 to 60 carbon atoms; R 3 is an organic group having an aliphatic hydrocarbon group having 5 to 60 carbon atoms; 1 , n 2 , n 3 and n 4 is 1;m 2 is 1) A group represented by the formula: Formula (d): [ka] (In the formula, * indicates bond position; X 8 indicates -O-;m 3 is 2 or 3; n 5 is 1;n 6 is 3;X7 is -O-;m 3 R 12 are each independently an alkyl group having 4 to 30 carbon atoms. A group represented by and the organic group having an aliphatic hydrocarbon group is present at the 2-position and / or 7-position of the fluorene compound. A fluorene compound represented by the formula: (ii) Formula (II): [ka] [In the formula, Ring A represents an aromatic ring; Y represents a hydroxyl group, a bromo group, or a chloro group; n represents an integer of 1 to 19; Rc' represents a divalent organic group having an aliphatic hydrocarbon group; rings A, B, and C each independently may have one or more selected from an organic group having an aliphatic hydrocarbon group and an electron-withdrawing group; when there are multiple rings A, each ring A may be the same or different; when there are multiple Ys, each Y may be the same or different; when there are multiple Rc's, each Rc' may be the same or different; Here, the divalent organic group having an aliphatic hydrocarbon group is Formula (a): [ka] (In the formula, Xa is absent or represents -O-, -S-, -NHCO-, or -CONH-; Rd represents an aliphatic hydrocarbon group having 5 or more carbon atoms; k 1 represents an integer of 1 to 10; when there are a plurality of Rd's, each Rd may be the same or different; when there are a plurality of Xa's, each Xa may be the same or different). is a group represented by The organic group having an aliphatic hydrocarbon group is Formula (b): [ka] (In the formula, * indicates bond position; X1 is -O-;R 1 is an aliphatic hydrocarbon group having 5 to 60 carbon atoms; m 1 is 1) A group represented by Formula (c): [ka] (In the formula, * indicates bond position; X 2 , X 2 ', X 2 '' and X 2 ''' is -O-;R 2 and R 4 are each independently an aliphatic hydrocarbon group having 5 to 60 carbon atoms; R 3 is an organic group having an aliphatic hydrocarbon group having 5 to 60 carbon atoms; 1 , n 2 , n 3 and n 4 is 1;m 2 is 1) A group represented by the formula: Formula (d): [ka] (In the formula, * indicates bond position; X 8 indicates -O-;m 3 is 2 or 3; n 5 is 1;n 6 is 3;X 7 is -O-;m 3 R 12 are each independently an alkyl group having 4 to 30 carbon atoms. A group represented by and the organic group having an aliphatic hydrocarbon group is present at the 2-position and / or 7-position of the fluorene compound. A fluorene compound represented by the formula: (iii) Formula (III): [ka] [In the formula, Y represents a hydroxyl group or an -NHR group (R represents a hydrogen atom, an alkyl group, or an aralkyl group); R a teeth, Formula (a): [ka] [In the formula, * indicates bond position; 1 represents an integer from 1 to 10; m 1 X 1 each independently represents a single bond, or -O-, -S-, -COO-, -OCONH-, -NHCO-, or -CONH-; R 1 and m 1 R 2 each independently represents a divalent aliphatic hydrocarbon group having 5 or more carbon atoms; and R 3 is a hydrogen atom, or Formula (III'): [ka] (In the formula, Y represents a hydroxyl group or an -NHR group (R represents a hydrogen atom, an alkyl group, or an aralkyl group); * represents a bonding position; n R b each independently represents an alkoxy group having 1 to 6 carbon atoms, a halogen atom, or an alkyl group having 1 to 6 carbon atoms which may be substituted with one or more halogen atoms; and n represents an integer of 0 to 4. is a group represented by the formula: A group represented by the formula: Formula (b): [ka] (In the formula, * indicates bond position; 2 indicates 1 or 2; n 1 , n 2 , n 3 and n 4 each independently represents an integer of 0 to 2; m 2 X 2 , m 2 X 2' and m 2 X 2 " each independently represents a single bond, or -O-, -S-, -COO-, -OCONH-, -NHCO-, or -CONH-; 2 R 4 and m 2 R 6 each independently represents an aliphatic hydrocarbon group having 5 or more carbon atoms; R 5 indicates an aliphatic hydrocarbon group having 5 or more carbon atoms. A group represented by the formula: Formula (c): [ka] (In the formula, * indicates bond position; 3 represents an integer from 0 to 15; n 5 represents an integer from 0 to 11; n 6 represents an integer from 0 to 5; m 3 X 3 each independently represents a single bond, or represents -O-, -S-, -COO-, -OCONH-, -NHCO-, or -CONH-; and m 3 R 7 each independently represents a hydrogen atom, a methyl group, or an aliphatic hydrocarbon group having 5 or more carbon atoms. A group represented by the formula: Formula (d): [ka] (In the formula, * indicates bond position; n 7 X 4 each independently represents a single bond, or -O-, -S-, -COO-, -OCONH-, -NHCO-, or -CONH-; R 8 represents a divalent aliphatic hydrocarbon group; n 7 R 9 each independently represents a monovalent aliphatic hydrocarbon group; n 7 represents an integer of 1 to 5; and Ar represents an arylene group. A group represented by wherein the total number of carbon atoms in the organic group is 30 or more; n R b each independently represents an alkoxy group having 1 to 6 carbon atoms, a halogen atom, or an alkyl group having 1 to 6 carbon atoms which may be substituted with one or more halogen atoms; and n represents an integer of 0 to 4. A benzyl compound represented by the formula: (iv) Formula (IV): [ka] [In the formula, Y represents a hydroxyl group or an -NHR group (R represents a hydrogen atom, an alkyl group, or an aralkyl group); k and l each independently represent an integer of 0 to 5, provided that k+l is not 0; k R a and l R b are each independently Formula (a): [ka] (In the formula, * indicates bond position; 1 represents an integer from 1 to 10; m 1 X 1 each independently represents nothing, -O-, -S-, -COO-, -OCONH-, or -CONH-; 1 R 1 each independently represents a divalent aliphatic hydrocarbon group having 5 or more carbon atoms. A group represented by Formula (b): [ka] (In the formula, * indicates bond position; 2 represents an integer between 1 and 2; m 2 n 1 , n 2 , n 3 and n 4 each independently represents an integer of 0 to 2; m 2 X2 , m 2 X 2 ',m 2 X 2 ''' and m 2 X 2 '' each independently represents absent, -O-, -S-, -COO-, -OCONH-, or -CONH-; 2 R 2 and R 4 each independently represents a hydrogen atom, a methyl group, or an aliphatic hydrocarbon group having 5 or more carbon atoms; R 3 indicates an aliphatic hydrocarbon group having 5 or more carbon atoms. A group represented by the formula: Formula (e): [ka] (In the formula, * indicates bond position; 3 represents an integer from 0 to 15; n 5 represents an integer from 0 to 11; n 6 represents an integer between 0 and 5; X 2 is absent or represents -O-, -S-, -NHCO- or -CONH-; 3 X 7 each independently represents absent, -O-, -S-, -COO-, -OCONH-, -NHCO- or -CONH-; 3 R 12 each independently represents a hydrogen atom, a methyl group, or an aliphatic hydrocarbon group having 5 or more carbon atoms. A group represented by In the above, the organic group having an aliphatic hydrocarbon group having 5 or more carbon atoms is selected from the group consisting of In an organic group having k+l aliphatic hydrocarbon groups, the total number of carbon atoms in all the aliphatic hydrocarbon groups is 16 or more; ring A is R a may have further substituents in addition to the ring B; b may further have a substituent in addition to the above. A compound represented by the formula: (v) Formula (V): [ka] [In the formula, k Q's each independently represent a single bond, -O-, -S-, -C(=O)O-, -C(=O)NH-, or -NH-; k R a each independently represents an organic group having at least one aliphatic hydrocarbon group having one or more branched chains, a total number of branched chains of 3 or more, and a total number of carbon atoms of 14 or more and 300 or less; k represents an integer of 1 to 4; R 1 is a hydrogen atom, or when Z is a group represented by the following formula (a), R 2 may be taken together with ring B to form a fluorene ring; ring A may be taken together with ring B to form a fluorene ring; 1 In addition to k QRa and C(X)(Y)Z, one or more substituents selected from the group consisting of a halogen atom, a C1-6 alkyl group optionally substituted by one or more halogen atoms, and a C1-6 alkoxy group optionally substituted by one or more halogen atoms; X represents a hydrogen atom or a phenyl group; Y represents a hydroxyl group or a -NHR group (R represents a hydrogen atom, an alkyl group or an aralkyl group); and Z represents a hydrogen atom or Formula (a): [ka] (In the formula, * represents a bonding position; m represents an integer of 0 to 4; m Qs each independently represent a single bond, -O-, -S-, -C(=O)O-, -C(=O)NH- or -NH-; m R b each independently represents an organic group having at least one aliphatic hydrocarbon group having one or more branched chains, a total number of branched chains of 3 or more, and a total number of carbon atoms of 14 or more and 300 or less; R 2 represents a hydrogen atom or R 1 may be taken together with ring A to form a fluorene ring; and ring B may be taken together with m QR b , and R 2and optionally having one or more substituents selected from the group consisting of a halogen atom, a C1-6 alkyl group optionally substituted by one or more halogen atoms, and a C1-6 alkoxy group optionally substituted by one or more halogen atoms. A group represented by indicates; R a and R b The organic group having at least one aliphatic hydrocarbon group having one or more branched chains, a total number of branched chains of 3 or more, and a total number of carbon atoms of 14 to 300, Formula (b): [ka] (In the formula, * indicates the bond position with the adjacent atom; R 3 and R 4 each independently represents a hydrogen atom or a C1-4 alkyl group; X 1 represents a single bond, a C1-4 alkylene group, or an oxygen atom, provided that R 3 and R 4 are never both hydrogen atoms) is a group having three or more identical or different divalent groups represented by the following formula: A branched chain-containing aromatic compound represented by the formula: (vi) Formula (VI): [ka] [In the formula, R 1 and R 5 is a hydrogen atom; R 2 , R 3 and R 4 is an alkoxy group having 8 to 30 carbon atoms; Rx is -CHO, -CH 2 OH, -CHR 6 -NHR 7 or CH 2 SH (where R 7 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, a benzyl group, or an alkoxy-substituted benzyl group; R 6represents a hydrogen atom, a phenyl group, or an alkoxy-substituted phenyl group), which is a group that binds to a carboxyl group, an amino group, or a hydroxyl group of an amino acid, a peptide, or an amino acid amide, or to a linker. A compound represented by the formula: (vii) Formula (VII): [ka] [In the formula, R 2 , R 4 and R 5 is a hydrogen atom, and R 1 and R 3 is an alkoxy group having 12 to 30 carbon atoms; RY is -CHO, -CH 2 OH, -CHR 6 -NHR 7 or CH 2 SH (where R 7 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, a benzyl group, or an alkoxy-substituted benzyl group; R 6 represents a hydrogen atom, a phenyl group, or an alkoxy-substituted phenyl group), which is a group that binds to a carboxyl group, an amino group, or a hydroxyl group of an amino acid, a peptide, or an amino acid amide, or to a linker. A compound represented by the formula: (viii) Formula (VIII): [ka] [In the formula, R 1 , R 3 and R 5 is a hydrogen atom, and R 2 and R 4 is an alkoxy group having 12 to 30 carbon atoms; RZ is -CHO, -CH 2 OH, -CHR 6 -NHR 7 or CH 2 SH (where R 7 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, a benzyl group, or an alkoxy-substituted benzyl group; R 6represents a hydrogen atom, a phenyl group, or an alkoxy-substituted phenyl group), which is a group that binds to a carboxyl group, an amino group, or a hydroxyl group of an amino acid, a peptide, or an amino acid amide, or to a linker. A compound represented by the formula: (ix) Formula (IX): [ka] [In the formula, X is -CH 2 ORa (wherein Ra represents a hydrogen atom, a halogenocarbonyl group, or an active ester type protecting group), —CH 2 NHRb (wherein Rb represents a hydrogen atom, a linear or branched alkyl group having 1 to 6 carbon atoms, or an aralkyl group), a halogenomethyl group, an azidomethyl group, a formyl group, or an oxime, which is a group that bonds to a carboxyl group, an amino group, or a hydroxyl group of an amino acid, a peptide, or an amino acid amide, or to a linker; R 1 , R 2 , R 3 , R 4 , and R 5 At least one of the formulas: -OR 6 -Xa-A, the remaining group being a hydrogen atom, a halogen atom, an alkyl group having 1 to 4 carbon atoms, or an alkoxy group having 1 to 4 carbon atoms; R 6 represents a linear or branched alkylene group having 1 to 16 carbon atoms, Xa represents O or CONRc (wherein Rc represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms); A represents Formula (1) ~ Formula (11) [ka] (where R 7 , R 8 and R 9 may be the same or different and represent a linear or branched alkyl group having 1 to 6 carbon atoms or an aryl group which may have a substituent; R 10 represents a single bond or a linear or branched alkylene group having 1 to 3 carbon atoms; R 11 , R 12 and R 13may be the same or different and represent a linear or branched alkylene group having 1 to 3 carbon atoms. represents either A compound represented by 3. The method of embodiment 1 or 2, wherein the monovalent group is derived from a compound selected from the group consisting of: (Embodiment 4) The method according to any one of embodiments 1 to 3, wherein the N-terminal protecting group is selected from the group consisting of a 9-fluorenylmethyloxycarbonyl group (Fmoc group), a tert-butoxycarbonyl group (Boc group), a benzyloxycarbonyl group (Cbz group), and an allyloxycarbonyl group (Alloc group). (Embodiment 5) After the condensation step, a capping step in which a reaction mixture containing an N-terminally and C-terminally protected peptide extended on the N-terminal side and a capping agent having an amino group are introduced into a flow reactor, and unreacted N-terminally protected amino acids or C-terminally activated derivatives of peptides are reacted with the capping agent in the flow reactor to inactivate the C-terminally activated derivatives; 5. The method according to any one of embodiments 1 to 4, further comprising: (Embodiment 6) 6. The method of embodiment 5, wherein the capping agent having an amino group is a compound selected from the group consisting of 2-(2-aminoethoxyethanol) (AEE) and 2-aminoethyl hydrogen sulfate (AEHS). (Embodiment 7) a C-terminal activation means having a flow reactor and a raw material introduction member for introducing an N-terminal protected amino acid or peptide whose N-terminal amino group is protected by an N-terminal protecting group, and a C-terminal activating agent into the flow reactor, which activates the C-terminal carboxyl group of the N-terminal protected amino acid or peptide in the flow reactor to form a C-terminal activated derivative of the N-terminal protected amino acid or peptide; a condensation means having a flow reactor and a raw material introducing member for introducing into the flow reactor a C-terminal activated derivative of an N-terminal protected amino acid or peptide, and a C-terminal protected amino acid or peptide whose C-terminal carboxyl group is protected by a tag protecting group, the condensation means comprising: a flow reactor; and a raw material introducing member for introducing into the flow reactor a C-terminal activated derivative of an N-terminal protected amino acid or peptide, and a C-terminal protected amino acid or peptide whose C-terminal carboxyl group is protected by a tag protecting group, the N-terminal protected amino acid or peptide being condensed to the N-terminal side of the C-terminal protected amino acid or peptide in the flow reactor to form an N-terminal and C-terminal protected peptide extended to the N-terminal side; N-terminal deprotection means, which has a flow reactor and a raw material introduction member for introducing an N-terminal and C-terminal protected peptide extended to the N-terminal side and a deprotecting agent for the N-terminal protecting group into the flow reactor, for deprotecting the N-terminal protecting group in the flow reactor to form a C-terminal protected peptide extended to the N-terminal side; and an extraction means having a mixing member for mixing a reaction mixture containing a C-terminal protected peptide extended on the N-terminus side with an aqueous phase, for mixing the reaction mixture containing the C-terminal protected peptide extended on the N-terminus side with the aqueous phase to extract the C-terminal protected peptide extended on the N-terminus side into an organic phase; An apparatus for producing a peptide comprising: (Embodiment 8) a capping means having a flow reactor and a raw material introduction member for introducing a reaction mixture containing an N-terminally and C-terminally protected peptide extended on the N-terminal side, and a capping agent having an amino group into the flow reactor, which reacts an unreacted C-terminal activated derivative of an N-terminally protected amino acid or peptide with the capping agent in the flow reactor to inactivate the C-terminal activated derivative; 8. The device of embodiment 7, further comprising: (Embodiment 9) The apparatus according to embodiment 7 or 8, wherein the C-terminal activation means, the condensation means and the N-terminal deprotection means have two or more inlet channels, a mixer that mixes the reaction liquid flowing in from the two or more inlet channels, one or more outlet channels that discharge the reaction liquid mixed in the mixer, a pump for delivering raw materials, and a temperature control device that controls the temperatures of the inlet channels, the outlet channel, the mixer, and the pump channels. (Embodiment 10) The apparatus according to any one of embodiments 7 to 9, wherein the extraction means comprises two or more inflow channels, a mixer for mixing an aqueous phase and a reaction solution containing a C-terminal protected peptide extended on the N-terminus side and flowing in from the two or more inflow channels, a phase separation member for separating a mixed phase of the reaction solution containing a C-terminal protected peptide extended on the N-terminus side and the aqueous phase mixed in the mixer into an organic phase and an aqueous phase, one or more outflow channels for discharging the organic phase separated by the phase separation member, and a pump for delivering the aqueous phase. (Embodiment 11) The device according to embodiment 9 or 10, wherein at least one of the C-terminal activation means, the condensation means and the N-terminal deprotection means has at least one physical property detection element selected from the group consisting of a pressure gauge, a flow meter and a thermometer in the inflow channel and / or the outflow channel. (Embodiment 12) The device according to embodiment 10 or 11, wherein the extraction means has at least one physical property detection member selected from the group consisting of a pressure gauge, a flow meter, and a thermometer, in the inflow passage and / or the outflow passage. (Embodiment 13) The apparatus according to any one of embodiments 7 to 12, wherein at least one of the C-terminal activation means, the condensation means, the N-terminal deprotection means and the extraction means has at least one compound detection member for detecting compounds contained in the raw materials and the reaction solution. (Embodiment 14) The device of embodiment 13, wherein the at least one compound detection member is at least one member selected from the group consisting of an ultraviolet-visible spectroscopic detector, a photodiode array detector, a fluorescence detector, a differential refractive index detector, an electrical conductivity detector, an evaporative light scattering detector, an infrared spectrometer, a near-infrared spectrometer, a nuclear magnetic resonance device, and a mass spectrometer. (Embodiment 15) The device according to embodiment 13 or 14, further comprising a compound separation member for separating a compound detected by the compound detection member, on the upstream side of the compound detection member in the flow path of the raw material, the reaction solution, etc. (Embodiment 16) The apparatus according to any one of embodiments 7 to 15, wherein at least one of the C-terminal activation means, the condensation means, the N-terminal deprotection means and the extraction means further has at least one outlet for sampling the reaction liquid. (Embodiment 17) The apparatus according to any one of embodiments 7 to 16, further comprising a circulation means for circulating the C-terminal protected peptide extended on the N-terminal side obtained in the extraction means into a raw material introduction member for the condensation step. Effect of the Invention
[0015] The present invention makes it possible to provide a means for producing a peptide with a reduced number of steps in a short period of time. [Brief description of the drawings]
[0016] [Figure 1] FIG. 1 is a flow chart showing each step in one embodiment of a method for producing a peptide according to one aspect of the present invention. [Diagram 2] FIG. 2 is a schematic diagram showing one embodiment of the peptide production apparatus according to one aspect of the present invention. [Diagram 3] FIG. 3 is a schematic diagram showing another embodiment of the peptide production apparatus according to an aspect of the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0017] Preferred embodiments of the present invention will now be described in detail.
[0018] <1. Method for producing peptides> The present inventors have found that in a method for producing a peptide using a flow reactor, by using a tag protecting group as a C-terminal protecting group, which allows separation and purification of the product by two-phase separation into an organic phase and an aqueous phase, it is possible to continuously perform a deprotection reaction of the N-terminal protecting group without purifying the peptide after the condensation reaction, thereby producing the peptide in a short time. Therefore, one aspect of the present invention relates to a method for producing a peptide.
[0019] A flow chart showing each step in one embodiment of the method of this aspect is shown in Figure 1. As shown in Figure 1, the method of this aspect includes a C-terminal activation step S1, a condensation step S2, an N-terminal deprotection step S4, and an extraction step S5. The method of this aspect may optionally include a capping step S3 and a C-terminal deprotection step S6. Each step is described in detail below.
[0020] [1-1. C-terminal activation step (S1)] This step involves introducing an N-terminal protected amino acid or peptide, whose N-terminal amino group is protected by an N-terminal protecting group, and a C-terminal activating agent into a flow reactor, and activating the C-terminal carboxyl group of the N-terminal protected amino acid or peptide in the flow reactor to form a C-terminal activated derivative of the N-terminal protected amino acid or peptide.
[0021] The N-terminal protected amino acids or peptide-constituting amino acids used in this step may be either natural or non-natural amino acids. When these amino acids have a side chain functional group, they preferably have a side chain protecting group that protects the functional group. Any amino acid and a peptide in which two or more of the amino acids are linked by peptide bonds can be used in this step. The chain length of the N-terminal protected peptide used in this step is usually 2 or more, for example, in the range of 2 to 50, particularly 2 to 30.
[0022] In the N-terminal protected amino acid or peptide used in this step, the N-terminal amino group, particularly the N-terminal α-amino group, is protected by an N-terminal protecting group. Examples of the N-terminal protecting group include, but are not limited to, 9-fluorenylmethyloxycarbonyl group (Fmoc group), tert-butoxycarbonyl group (Boc group), benzyloxycarbonyl group (Cbz group), and allyloxycarbonyl group (Alloc group). The N-terminal protecting group is preferably an Fmoc group or a Boc group, more preferably an Fmoc group. The Fmoc group or the Boc group can be deprotected by base or acid treatment. Therefore, compared with a protecting group (e.g., a Cbz group) that is deprotected by catalytic reduction using a catalytic metal powder, the Fmoc group or the Boc group can easily carry out the deprotection reaction by base or acid treatment in a flow reactor in the N-terminal deprotection step described below. In the case of the Boc group, it may be preferable to apply it to the N-terminal protection of an amino acid or peptide that does not contain cysteine or methionine. However, since the Fmoc group can be applied to the protection of the N-terminus of various amino acids or peptides, it is particularly preferable to use the Fmoc group as the N-terminus protecting group. By carrying out the method of this embodiment using the N-terminus protecting groups exemplified above, a peptide can be produced with fewer steps and in a short time.
[0023] The N-terminal protected amino acid or peptide used in this step may be prepared by purchasing a commercially available product, or may be prepared by self-synthesis according to a known method.
[0024] The C-terminal activating agent used in this step refers to a compound capable of reacting with the C-terminal carboxyl group of an amino acid or peptide to form a highly electrophilic activated derivative. The C-terminal activating agent is usually selected from the group consisting of alkyl formate halides, carboxylic acid halides, phosgene and phosgene equivalents, and C-terminal activated condensing agents. The C-terminal activating agent is preferably selected from the group consisting of halogenated ethyl formate, halogenated isopropyl formate, halogenated isobutyl formate, carboxylic acid halides, phosgene and phosgene equivalents, carbodiimide-based condensing agents, phosphonium-based condensing agents, uronium-based condensing agents, haluronium-based condensing agents, imidazole-based condensing agents, triazine-based condensing agents, and condensation additives, and is preferably selected from the group consisting of halogenated alkyl formates such as halogenated ethyl formate, halogenated isopropyl formate, and halogenated isobutyl formate; carboxylic acid halides; phosgene and phosgene equivalents; dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIC), and N-ethyl-N'-3-dimethylaminopropylcarbodiimide, carbodiimide-based condensing agents such as benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate (PyBop); uronium-based condensing agents such as [O-(7-azobenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate] (HATU), O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU), and (1-cyano-2-ethoxy-2-oxoethylideneaminooxy)dimethylamino-morpholino-carbenium hexafluorophosphate (COMU); 2-chloro-1,3-dimethylimidazolinium Halouronium condensing agents such as hexafluorophosphate (CIP) and 1-(chloro-1-pyrrolidinylmethylene)pyrrolidinium hexafluorophosphate (PyCIU); imidazole condensing agents such as N,N'-carbonyldiimidazole (CDI) and 1,1'-carbonyldi(1,2,4-triazole) (CDT); 4-(4,6-dimethoxy-1,3,It is more preferably selected from the group consisting of triazine-based condensing agents such as 5-triazin-2-yl)-4-methylmorpholinium chloride (DMT-MM); and condensation additives such as 1-hydroxybenzotriazole (HOBt) and 1-hydroxy-7-azabenzotriazole (HOAt), and more preferably selected from the group consisting of isobutyl chloroformate (IBCF), isopropyl chloroformate, ethyl chloroformate, isobutyl bromoformate, isopropyl bromoformate, ethyl bromoformate, triphosgene, diphosgene, thiophosgene, carbonyldiimidazole, pivaloyl chloride, adamantanecarbonyl chloride, isostearic acid chloride, pivaloyl bromide, adamantanecarbonyl bromide, and isostearic acid bromide, and IBCF is particularly preferred. The C-terminal activating agent exemplified above may be used alone or in combination of two or more. A C-terminal activating agent and, for example, N,A nucleophilic base catalyst such as N-dimethylaminopyridine or N-methylimidazole may be used in the presence of the nucleophilic base catalyst. In the art, a C-terminal activated condensing agent such as EDC·HCl and a condensation additive such as HOBt are usually used in combination for condensation of amino acids or peptides. Such a C-terminal activated condensing agent can react with the C-terminal carboxyl group of an amino acid or peptide to form a relatively mildly electrophilic activated derivative. For this reason, when a condensation reaction is carried out using a C-terminal activated condensing agent, racemization can be avoided and a peptide bond can be formed stereoselectively. When a condensation reaction is carried out using an alkyl formate halide, a carboxylic acid halide, phosgene or a phosgene equivalent among the C-terminal activating agents exemplified above, the by-products generated after the condensation reaction are carbon dioxide and hydrogen chloride, etc., and the reaction solution containing the peptide can be used in the next step as it is without purifying the product peptide from the reaction solution. In addition, the C-terminal activating agents exemplified above can form highly electrophilic activated derivatives, so that racemization is likely to proceed. However, in the method of this embodiment, the condensation reaction is carried out in a flow reactor in which the reaction can proceed in a short time in the condensation step described below, so that racemization can be substantially avoided. Therefore, by carrying out the method of this embodiment using the C-terminal activating agent exemplified above, a peptide can be produced in a short time with fewer steps.
[0025] The C-terminal activating agent used in this step may be prepared by purchasing a commercially available product, or may be prepared by self-synthesis according to a known method.
[0026] The C-terminal activator used in this step usually reacts with a carboxyl group under basic conditions. For this reason, it is preferable to react the C-terminal activator with an N-terminal protected amino acid or peptide in the presence of a base. The base is not limited to, but may be, for example, a base with low nucleophilicity such as trialkylamine. The base is preferably N,N-diisopropylethylamine (DIEA), tributylamine, triethylamine, etc., and more preferably DIEA or tributylamine. The above-mentioned exemplified base is introduced into the flow reactor together with the N-terminal protected amino acid or peptide or the C-terminal activator, preferably together with the N-terminal protected amino acid or peptide. Alternatively, the bases may not be introduced into the flow reactor together with the N-terminal protected amino acid or peptide or the C-terminal activator, but may be introduced into the flow reactor independently, and then mixed in a mixer to prepare a solution inside the flow reactor. By reacting the C-terminal activator with the N-terminal protected amino acid or peptide in the presence of the above-mentioned base, an activated derivative can be formed with high efficiency.
[0027] This step can be carried out by introducing a solution containing an N-terminal protected amino acid or peptide in a solvent and a solution containing a C-terminal activating agent in a solvent into a flow reactor at a predetermined flow rate. Examples of the solvent include, but are not limited to, hydrophilic organic solvents such as N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), tetrahydrofuran (THF), isopropyl acetate, and acetonitrile, as well as hydrophobic organic solvents such as cyclopentyl methyl ether (CPME), 2-methyltetrahydrofuran, 4-methyltetrahydropyran (MTHP), dichloromethane, and t-butyl methyl ether (MTBE). The solution containing the N-terminal protected amino acid or peptide preferably contains the hydrophilic organic solvent exemplified above as a solvent, and more preferably contains DMF as a solvent. The solution containing the C-terminal activating agent preferably contains the hydrophobic organic solvent exemplified above as a solvent, and more preferably contains CPME or MTHP as a solvent. By using the solvents exemplified above, a solution containing an N-terminal protected amino acid or peptide and a solution containing a C-terminal activating agent can be successfully prepared.
[0028] The base and solvent used in this step may be prepared by, for example, purchasing commercially available products.
[0029] In this embodiment, the solution containing the N-terminal protected amino acid or peptide preferably contains the base exemplified above. In the solution containing the N-terminal protected amino acid or peptide, the amount of the N-terminal protected amino acid or peptide is preferably in the range of 1.0 to 5.0 molar equivalents relative to the C-terminal protected amino acid or peptide, more preferably in the range of 1.0 to 1.3 molar equivalents. The amount of the base is preferably in the range of 1.0 to 5.0 molar equivalents relative to the C-terminal protected amino acid or peptide, more preferably in the range of 1.0 to 1.3 molar equivalents. In the solution containing the C-terminal activator, the amount of the C-terminal activator is preferably in the range of 1.0 to 5.0 molar equivalents relative to the C-terminal protected amino acid or peptide, more preferably in the range of 1.0 to 1.3 molar equivalents. When the amount of the component is less than the lower limit, the formation rate of the activated derivative may decrease. Also, when the amount of the component exceeds the upper limit, these components may not be sufficiently dissolved in the solvent and may precipitate in the flow reactor. When the components precipitate, the flow reactor may become clogged. By carrying out this step in the above-mentioned range of amounts, it is possible to form an activated derivative with high efficiency and produce a peptide in a short time without causing clogging of the flow reactor.
[0030] In the case of the above embodiment, the flow rate of the solution containing the N-terminal protected amino acid or peptide introduced into the flow reactor is preferably in the range of 0.1 to 100 mL / min, more preferably in the range of 0.5 to 20 mL / min. The flow rate of the solution containing the C-terminal activator introduced into the flow reactor is preferably in the range of 0.1 to 100 mL / min, more preferably in the range of 0.5 to 20 mL / min. If the flow rate is below the lower limit, the production time of the peptide by the method of this aspect may be extended. By carrying out this step at a flow rate within the above range, an activated derivative can be formed with high efficiency and the peptide can be produced in a short time.
[0031] In this step, the temperature of the reaction for forming the activated derivative in the flow reactor is preferably in the range of 0 to 100°C, and more preferably in the range of 20 to 60°C. If the temperature of the activation reaction is below the lower limit, the yield of the reaction for forming the activated derivative may decrease. If the temperature of the reaction for forming the activated derivative exceeds the upper limit, by-products may be produced. By carrying out this step at a temperature within the above range, the C-terminal activated derivative of the N-terminal protected amino acid or peptide can be formed in high yield.
[0032] In this step, the time for the reaction to form the activated derivative in the flow reactor is preferably in the range of 0.05 seconds to 30 minutes, and more preferably in the range of 0.1 to 30 seconds. If the time for the reaction to form the activated derivative is less than the lower limit, the yield of the reaction to form the activated derivative may decrease. If the time for the reaction to form the activated derivative exceeds the upper limit, by-products may be produced. By carrying out this step for a time in the above range, the C-terminal activated derivative of the N-terminal protected amino acid or peptide can be formed in high yield.
[0033] By carrying out this step under the above-mentioned conditions, the C-terminal carboxyl group of the N-terminal protected amino acid or peptide can be activated in the flow reactor to form a C-terminal activated derivative of the N-terminal protected amino acid or peptide.
[0034] [1-2. Condensation step (S2)] This process involves introducing into a flow reactor a C-terminally activated derivative of an N-terminally protected amino acid or peptide and a C-terminally protected amino acid or peptide in which the C-terminal carboxyl group is protected with a tag protecting group, and condensing the N-terminally protected amino acid or peptide to the N-terminal side of the C-terminally protected amino acid or peptide in the flow reactor to form an N- and C-terminally protected peptide extended on the N-terminal side.
[0035] The C-terminal activated derivative of the N-terminal protected amino acid or peptide used in this step can be obtained in the C-terminal activation step described above.
[0036] The C-terminal protected amino acid or peptide-constituting amino acid used in this step may be either a natural or non-natural amino acid. When these amino acids have a side chain functional group, they preferably have a side chain protecting group that protects the functional group. Any amino acid and a peptide in which two or more of the amino acids are linked by peptide bonds can be used in this step. The chain length of the N-terminal protected peptide used in this step is usually 2 or more, for example, in the range of 2 to 50, particularly 2 to 30.
[0037] The C-terminal protected amino acid or peptide used in this step has its C-terminal carboxyl group protected by a tag protecting group. The tag protecting group used in this step is a protecting group for the C-terminal carboxyl group of an amino acid or peptide, and means a protecting group that reduces the polarity so that the amino acid or peptide, or its condensation product, can be separated and purified by two-phase separation of an organic phase and an aqueous phase. Examples of the tag protecting group include, but are not limited to, a protecting group made of a benzyl compound described in Patent Document 1 and a pseudo-solid-phase protecting group described in Patent Document 2.
[0038] The tag protecting group is preferably a monovalent group derived from a compound selected from the group consisting of compounds represented by the following formulas (I) to (IX). (i) Formula (I): [ka] [In the formula, ring A represents an aromatic ring; Y represents a hydroxyl group, a bromo group, or a chloro group; Ra, Rb, and Rc each independently represent an organic group having an aliphatic hydrocarbon group, a hydrogen atom, or an electron-withdrawing group, and at least one of Ra, Rb, and Rc is an organic group having an aliphatic hydrocarbon group; rings A, B, and C each independently may have an electron-withdrawing group; Here, the organic group having an aliphatic hydrocarbon group is Formula (b): [ka] (In the formula, * indicates bond position; X 1 is -O-;R 1 is an aliphatic hydrocarbon group having 5 to 60 carbon atoms; m 1 is 1) A group represented by Formula (c): [ka] (In the formula, * indicates bond position; X 2 , X 2 ', X 2 '' and X 2 ''' is -O-;R 2 and R 4 are each independently an aliphatic hydrocarbon group having 5 to 60 carbon atoms; R 3 is an organic group having an aliphatic hydrocarbon group having 5 to 60 carbon atoms; 1 , n 2 , n 3 and n 4 is 1;m 2 is 1) A group represented by the formula: Formula (d): [ka] (In the formula, * indicates bond position; X 8 indicates -O-;m 3 is 2 or 3; n 5 is 1;n 6 is 3;X 7 is -O-;m 3 R 12 are each independently an alkyl group having 4 to 30 carbon atoms. A group represented by and the organic group having an aliphatic hydrocarbon group is present at the 2-position and / or 7-position of the fluorene compound. A fluorene compound represented by the formula: (ii) Formula (II): [ka] [In the formula, Ring A represents an aromatic ring; Y represents a hydroxyl group, a bromo group, or a chloro group; n represents an integer of 1 to 19; Rc' represents a divalent organic group having an aliphatic hydrocarbon group; rings A, B, and C each independently may have one or more selected from an organic group having an aliphatic hydrocarbon group and an electron-withdrawing group; when there are multiple rings A, each ring A may be the same or different; when there are multiple Ys, each Y may be the same or different; when there are multiple Rc's, each Rc' may be the same or different; Here, the divalent organic group having an aliphatic hydrocarbon group is Formula (a): [ka] (In the formula, Xa is absent or represents -O-, -S-, -NHCO-, or -CONH-; Rd represents an aliphatic hydrocarbon group having 5 or more carbon atoms; k 1 represents an integer of 1 to 10; when there are a plurality of Rd's, each Rd may be the same or different; when there are a plurality of Xa's, each Xa may be the same or different). is a group represented by The organic group having an aliphatic hydrocarbon group is Formula (b): [ka] (In the formula, * indicates bond position; X 1 is -O-;R 1 is an aliphatic hydrocarbon group having 5 to 60 carbon atoms; m 1 is 1) A group represented by Formula (c): [ka] (In the formula, * indicates bond position; X 2 , X 2', X 2 '' and X 2 ''' is -O-;R 2 and R 4 are each independently an aliphatic hydrocarbon group having 5 to 60 carbon atoms; R 3 is an organic group having an aliphatic hydrocarbon group having 5 to 60 carbon atoms; 1 , n 2 , n 3 and n 4 is 1;m 2 is 1) A group represented by the formula: Formula (d): [ka] (In the formula, * indicates bond position; X 8 indicates -O-;m 3 is 2 or 3; n 5 is 1;n 6 is 3;X 7 is -O-;m 3 R 12 are each independently an alkyl group having 4 to 30 carbon atoms. A group represented by and the organic group having an aliphatic hydrocarbon group is present at the 2-position and / or 7-position of the fluorene compound. A fluorene compound represented by the formula: (iii) Formula (III): [ka] [In the formula, Y represents a hydroxyl group or an -NHR group (R represents a hydrogen atom, an alkyl group, or an aralkyl group); R a teeth, Formula (a): [ka] [In the formula, * indicates bond position; 1 represents an integer from 1 to 10; m 1 X1 each independently represents a single bond, or -O-, -S-, -COO-, -OCONH-, -NHCO-, or -CONH-; R 1 and m 1 R 2 each independently represents a divalent aliphatic hydrocarbon group having 5 or more carbon atoms; and R 3 is a hydrogen atom, or Formula (III'): [ka] (In the formula, Y represents a hydroxyl group or an -NHR group (R represents a hydrogen atom, an alkyl group, or an aralkyl group); * represents a bonding position; n R b each independently represents an alkoxy group having 1 to 6 carbon atoms, a halogen atom, or an alkyl group having 1 to 6 carbon atoms which may be substituted with one or more halogen atoms; and n represents an integer of 0 to 4. is a group represented by the formula: A group represented by the formula: Formula (b): [ka] (In the formula, * indicates bond position; 2 indicates 1 or 2; n 1 , n 2 , n 3 and n 4 each independently represents an integer of 0 to 2; m 2 X 2 , m 2 X 2 ' and m 2 X 2 " each independently represents a single bond, or -O-, -S-, -COO-, -OCONH-, -NHCO-, or -CONH-; 2 R 4 and m 2 R 6 each independently represents an aliphatic hydrocarbon group having 5 or more carbon atoms; R 5 indicates an aliphatic hydrocarbon group having 5 or more carbon atoms. A group represented by the formula: Formula (c): [ka] (In the formula, * indicates bond position; 3 represents an integer from 0 to 15; n 5 represents an integer from 0 to 11; n 6 represents an integer from 0 to 5; m 3 X 3 each independently represents a single bond, or represents -O-, -S-, -COO-, -OCONH-, -NHCO-, or -CONH-; and m 3 R 7 each independently represents a hydrogen atom, a methyl group, or an aliphatic hydrocarbon group having 5 or more carbon atoms. A group represented by the formula: Formula (d): [ka] (In the formula, * indicates bond position; n 7 X 4 each independently represents a single bond, or -O-, -S-, -COO-, -OCONH-, -NHCO-, or -CONH-; R 8 represents a divalent aliphatic hydrocarbon group; n 7 R 9 each independently represents a monovalent aliphatic hydrocarbon group; n 7 represents an integer of 1 to 5; and Ar represents an arylene group. A group represented by wherein the total number of carbon atoms in the organic group is 30 or more; n R b each independently represents an alkoxy group having 1 to 6 carbon atoms, a halogen atom, or an alkyl group having 1 to 6 carbon atoms which may be substituted with one or more halogen atoms; and n represents an integer of 0 to 4. A benzyl compound represented by the formula: (iv) Formula (IV): [ka] [In the formula, Y represents a hydroxyl group or an -NHR group (R represents a hydrogen atom, an alkyl group, or an aralkyl group); k and l each independently represent an integer of 0 to 5, provided that k+l is not 0; k R a and l R b are each independently Formula (a): [ka] (In the formula, * indicates bond position; 1 represents an integer from 1 to 10; m 1 X 1 each independently represents nothing, -O-, -S-, -COO-, -OCONH-, or -CONH-; 1 R 1 each independently represents a divalent aliphatic hydrocarbon group having 5 or more carbon atoms. A group represented by Formula (b): [ka] (In the formula, * indicates bond position; 2 represents an integer between 1 and 2; m 2 n 1 , n 2 , n 3 and n 4 each independently represents an integer of 0 to 2; m 2 X 2 , m 2 X 2 ',m 2 X 2 ''' and m 2 X 2 '' each independently represents absent, -O-, -S-, -COO-, -OCONH-, or -CONH-; 2 R 2 and R 4each independently represents a hydrogen atom, a methyl group, or an aliphatic hydrocarbon group having 5 or more carbon atoms; R 3 indicates an aliphatic hydrocarbon group having 5 or more carbon atoms. A group represented by the formula: Formula (e): [ka] (In the formula, * indicates bond position; 3 represents an integer from 0 to 15; n 5 represents an integer from 0 to 11; n 6 represents an integer between 0 and 5; X 2 is absent or represents -O-, -S-, -NHCO- or -CONH-; 3 X 7 each independently represents absent, -O-, -S-, -COO-, -OCONH-, -NHCO- or -CONH-; 3 R 12 each independently represents a hydrogen atom, a methyl group, or an aliphatic hydrocarbon group having 5 or more carbon atoms. A group represented by In the above, the organic group having an aliphatic hydrocarbon group having 5 or more carbon atoms is selected from the group consisting of In an organic group having k+l aliphatic hydrocarbon groups, the total number of carbon atoms in all the aliphatic hydrocarbon groups is 16 or more; ring A is R a may have further substituents in addition to the ring B; b may further have a substituent in addition to the above. A compound represented by the formula: (v) Formula (V): [ka] [In the formula, k Q's each independently represent a single bond, -O-, -S-, -C(=O)O-, -C(=O)NH-, or -NH-; k R aeach independently represents an organic group having at least one aliphatic hydrocarbon group having one or more branched chains, a total number of branched chains of 3 or more, and a total number of carbon atoms of 14 or more and 300 or less; k represents an integer of 1 to 4; R 1 is a hydrogen atom, or when Z is a group represented by the following formula (a), R 2 may be taken together with ring B to form a fluorene ring; ring A may be taken together with ring B to form a fluorene ring; 1 In addition to k QRa and C(X)(Y)Z, one or more substituents selected from the group consisting of a halogen atom, a C1-6 alkyl group optionally substituted by one or more halogen atoms, and a C1-6 alkoxy group optionally substituted by one or more halogen atoms; X represents a hydrogen atom or a phenyl group; Y represents a hydroxyl group or a -NHR group (R represents a hydrogen atom, an alkyl group or an aralkyl group); and Z represents a hydrogen atom or Formula (a): [ka] (In the formula, * represents a bonding position; m represents an integer of 0 to 4; m Qs each independently represent a single bond, -O-, -S-, -C(=O)O-, -C(=O)NH- or -NH-; m R b each independently represents an organic group having at least one aliphatic hydrocarbon group having one or more branched chains, a total number of branched chains of 3 or more, and a total number of carbon atoms of 14 or more and 300 or less; R 2 represents a hydrogen atom or R 1 may be taken together with ring A to form a fluorene ring; and ring B may be taken together with m QR b , and R 2 and optionally having one or more substituents selected from the group consisting of a halogen atom, a C1-6 alkyl group optionally substituted by one or more halogen atoms, and a C1-6 alkoxy group optionally substituted by one or more halogen atoms. A group represented by indicates; R a and Rb The organic group having at least one aliphatic hydrocarbon group having one or more branched chains, a total number of branched chains of 3 or more, and a total number of carbon atoms of 14 to 300, Formula (b): [ka] (In the formula, * indicates the bond position with the adjacent atom; R 3 and R 4 each independently represents a hydrogen atom or a C1-4 alkyl group; X 1 represents a single bond, a C1-4 alkylene group, or an oxygen atom, provided that R 3 and R 4 are never both hydrogen atoms) is a group having three or more identical or different divalent groups represented by the following formula: A branched chain-containing aromatic compound represented by the formula: (vi) Formula (VI): [ka] [In the formula, R 1 and R 5 is a hydrogen atom; R 2 , R 3 and R 4 is an alkoxy group having 8 to 30 carbon atoms; Rx is -CHO, -CH 2 OH, -CHR 6 -NHR 7 or CH 2 SH (where R 7 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, a benzyl group, or an alkoxy-substituted benzyl group; R 6 represents a hydrogen atom, a phenyl group, or an alkoxy-substituted phenyl group), which is a group that binds to a carboxyl group, an amino group, or a hydroxyl group of an amino acid, a peptide, or an amino acid amide, or to a linker. A compound represented by the formula: (vii) Formula (VII): [ka] [In the formula, R 2 , R 4 and R 5 is a hydrogen atom, and R 1 and R 3 is an alkoxy group having 12 to 30 carbon atoms; RY is -CHO, -CH 2 OH, -CHR 6 -NHR 7 or CH 2 SH (where R 7 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, a benzyl group, or an alkoxy-substituted benzyl group; R 6 represents a hydrogen atom, a phenyl group, or an alkoxy-substituted phenyl group), which is a group that binds to a carboxyl group, an amino group, or a hydroxyl group of an amino acid, a peptide, or an amino acid amide, or to a linker. A compound represented by the formula: (viii) Formula (VIII): [ka] [In the formula, R 1 , R 3 and R 5 is a hydrogen atom, and R 2 and R 4 is an alkoxy group having 12 to 30 carbon atoms; RZ is -CHO, -CH 2 OH, -CHR 6 -NHR 7 or CH 2 SH (where R 7 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, a benzyl group, or an alkoxy-substituted benzyl group; R 6 represents a hydrogen atom, a phenyl group, or an alkoxy-substituted phenyl group), which is a group that binds to a carboxyl group, an amino group, or a hydroxyl group of an amino acid, a peptide, or an amino acid amide, or to a linker. A compound represented by the formula: (ix) Formula (IX): [ka] [In the formula, X is -CH 2ORa (wherein Ra represents a hydrogen atom, a halogenocarbonyl group, or an active ester type protecting group), —CH 2 NHRb (wherein Rb represents a hydrogen atom, a linear or branched alkyl group having 1 to 6 carbon atoms, or an aralkyl group), a halogenomethyl group, an azidomethyl group, a formyl group, or an oxime, which is a group that bonds to a carboxyl group, an amino group, or a hydroxyl group of an amino acid, a peptide, or an amino acid amide, or to a linker; R 1 , R 2 , R 3 , R 4 , and R 5 At least one of the formulas: -OR 6 -Xa-A, the remaining group being a hydrogen atom, a halogen atom, an alkyl group having 1 to 4 carbon atoms, or an alkoxy group having 1 to 4 carbon atoms; R 6 represents a linear or branched alkylene group having 1 to 16 carbon atoms, Xa represents O or CONRc (wherein Rc represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms); A represents Formula (1) ~ Formula (11) [ka] (where R 7 , R 8 and R 9 may be the same or different and represent a linear or branched alkyl group having 1 to 6 carbon atoms or an aryl group which may have a substituent; R 10 represents a single bond or a linear or branched alkylene group having 1 to 3 carbon atoms; R 11 , R 12 and R 13 may be the same or different and represent a linear or branched alkylene group having 1 to 3 carbon atoms. represents either A compound represented by the formula:
[0039] The tag protecting groups have the formula TIPS2-OP, TIPS3-OMP, TIPS3-MMP, TIPS3-O, TIPS6-OP, TIPS6-MMP, TIPS9-OMP and TBDPS2-OP: [ka] TIFF2024160485000057.tif233159TIFF2024160485000058.tif208160TIFF2024160485000059.tif93154[In the formula, X 1 -CH 2 OR 1 , or -CH 2 NHR 2 and R 1 is a hydrogen atom, a halogenocarbonyl group, or an active ester type protecting group, R 2 is a hydrogen atom, a linear or branched alkyl group having 1 to 6 carbon atoms, or an aralkyl group, R 5b is a hydrogen atom, a halogen atom, an alkyl group having 1 to 4 carbon atoms, or an alkoxy group having 1 to 4 carbon atoms.] It is more preferable that the monovalent group is derived from a compound selected from the group consisting of compounds represented by the formula: 1 -CH 2 OH or -CH 2 NH 2 is preferably -CH 2 More preferably, R is OH. 5b is preferably a hydrogen atom. Particularly preferably, in the formula TIPS2-OP, X 1 But -CH 2 OH and R 5b is a hydrogen atom (TIPS2-OH). The above-exemplified compounds are described in Patent Documents 1 and 2.
[0040] The monovalent group exemplified above is usually a free group resulting from the elimination of a hydrogen atom from a hydroxyl group of the corresponding compound. By carrying out this step using the tag protecting group exemplified above, it is possible to substantially prevent the N-terminal and C-terminal protected peptides extended to the N-terminal side obtained by the condensation reaction from precipitating in the flow reactor. In addition, in the extraction step described below, the C-terminal protected peptides extended to the N-terminal side can be easily extracted by two-phase separation of the organic phase and the aqueous phase. Therefore, the method of this embodiment allows the production of peptides with fewer steps and in a short time.
[0041] The C-terminal protected amino acid or peptide used in this step may be prepared by, for example, purchasing a commercially available product, or may be prepared by self-synthesis based on known methods described in, for example, Patent Documents 1 and 2.
[0042] This step can be carried out by introducing a solution containing a C-terminal activated derivative of an N-terminal protected amino acid or peptide in a solvent and a solution containing a C-terminal protected amino acid or peptide in a solvent into a flow reactor at a predetermined flow rate. The solvent can be the same as the solvent exemplified in the explanation of the C-terminal activation step. The solution containing a C-terminal activated derivative of an N-terminal protected amino acid or peptide usually contains the solvent used in the C-terminal activation step. The solution containing a C-terminal protected amino acid or peptide preferably contains the hydrophilic organic solvent exemplified above as a solvent, and more preferably contains DMF as a solvent. By using the solvent exemplified above, a solution containing a C-terminal activated derivative of an N-terminal protected amino acid or peptide and a solution containing a C-terminal protected amino acid or peptide can be successfully prepared.
[0043] The solvent used in this step may be prepared by, for example, purchasing a commercially available product.
[0044] In the present embodiment, it is preferable to use the reaction mixture containing the N-terminal protected amino acid or C-terminal activated derivative of peptide obtained in the C-terminal activation step as it is as the solution containing the N-terminal protected amino acid or C-terminal activated derivative of peptide. By using the reaction mixture containing the N-terminal protected amino acid or C-terminal activated derivative of peptide obtained in the C-terminal activation step as it is in this step, the peptide can be produced with fewer steps and in a short time.
[0045] In the case of the above embodiment, in the solution containing the C-terminal activated derivative of the N-terminal protected amino acid or peptide, the amount of the C-terminal activated derivative of the N-terminal protected amino acid or peptide is preferably in the range of 1.0 to 5.0 molar equivalents relative to the C-terminal protected amino acid or peptide, and more preferably in the range of 1.0 to 1.3 molar equivalents. When the reaction mixture containing the C-terminal activated derivative of the N-terminal protected amino acid or peptide obtained in the C-terminal activation step is used as it is, the amount of the C-terminal activated derivative of the N-terminal protected amino acid or peptide may vary within the above range depending on the reaction yield in the C-terminal activation step. In the solution containing the C-terminal protected amino acid or peptide, the concentration of the C-terminal protected amino acid or peptide is preferably in the range of 0.01 to 1.0 mol / L, and more preferably in the range of 0.05 to 0.3 mol / L. When the amount or concentration of the component is less than the lower limit, the yield of the condensation reaction may decrease. Also, when the amount or concentration of the component exceeds the upper limit, these components may not be sufficiently dissolved in the solvent and may precipitate in the flow reactor. When the components precipitate, the flow reactor may become clogged. By carrying out this step in the amount or concentration within the above range, an activated derivative can be formed with high efficiency, and the peptide can be produced in a short time without causing clogging of the flow reactor.
[0046] In the case of the above embodiment, the flow rate of the solution containing the N-terminal protected amino acid or C-terminal activated derivative of the peptide introduced into the flow reactor is preferably in the range of 0.1 to 100 mL / min, more preferably in the range of 0.5 to 20 mL / min. When the reaction mixture containing the N-terminal protected amino acid or C-terminal activated derivative of the peptide obtained in the C-terminal activation step is used as it is, the flow rate of the solution containing the N-terminal protected amino acid or C-terminal activated derivative of the peptide may vary within the above range depending on the flow rate of each solution in the C-terminal activation step. The flow rate of the solution containing the C-terminal protected amino acid or peptide introduced into the flow reactor is preferably in the range of 0.2 to 200 mL / min, more preferably in the range of 1 to 40 mL / min. If the flow rate is less than the lower limit, the production time of the peptide by the method of this aspect may be extended. In addition, if the flow rate exceeds the upper limit, the yield of the condensation reaction may be reduced. By carrying out this step at a flow rate within the above range, it is possible to form an N-terminal and C-terminal protected peptide extended to the N-terminus side in high yield and produce the peptide in a short time.
[0047] In this step, the temperature of the condensation reaction between the C-terminal protected amino acid or peptide and the N-terminal protected amino acid or peptide in the flow reactor is preferably in the range of 0 to 100°C, more preferably in the range of 20 to 60°C. If the temperature of the condensation reaction is below the lower limit, the yield of the condensation reaction may decrease. If the temperature of the condensation reaction exceeds the upper limit, racemization may proceed. By carrying out this step at a temperature within the above range, a peptide having the desired absolute configuration can be produced in high yield.
[0048] In this step, the time for the condensation reaction between the C-terminal protected amino acid or peptide and the N-terminal protected amino acid or peptide in the flow reactor is preferably in the range of 1 second to 60 minutes, and more preferably in the range of 10 seconds to 5 minutes. If the time for the condensation reaction is less than the lower limit, the yield of the condensation reaction may decrease. If the time for the condensation reaction exceeds the upper limit, racemization may proceed. By carrying out this step for a time in the above range, a peptide having the desired absolute configuration can be produced in high yield.
[0049] By carrying out this step under the above-mentioned conditions, an N-terminally protected amino acid or peptide can be condensed to the N-terminal side of a C-terminally protected amino acid or peptide in a flow reactor, thereby forming an N-terminally and C-terminally protected peptide extended to the N-terminal side.
[0050] [1-3. Capping process (S3)] This step involves introducing a reaction mixture containing an N-terminally and C-terminally protected peptide extended on the N-terminus side and a capping agent having an amino group into a flow reactor, and reacting unreacted N-terminally protected amino acids or C-terminal activated derivatives of peptides with the capping agent in the flow reactor to inactivate the C-terminal activated derivatives.
[0051] This step is preferably carried out after the condensation step, and more preferably carried out after the condensation step using a reaction mixture containing the N-terminal and C-terminal protected peptide extended to the N-terminus obtained in the condensation step.
[0052] The capping agent used in this step refers to a compound having an amino group, which can react with an unreacted N-terminal protected amino acid or C-terminal activated derivative of a peptide to inactivate the unreacted N-terminal protected amino acid or C-terminal activated derivative of a peptide. The capping agent preferably has an additional hydrophilic group such as a hydroxyl group or a sulfate group in addition to the amino group. By having an additional hydrophilic group, the water solubility of the reaction product with the N-terminal protected amino acid or C-terminal activated derivative of a peptide can be improved. This allows the reaction product with the inactivated capping agent to be transferred to the aqueous phase in the extraction step described below. The capping agent is preferably selected from the group consisting of 2-(2-aminoethoxyethanol) (AEE) and 2-aminoethyl hydrogen sulfate (AEHS), and more preferably AEE. By using the capping agent exemplified above, the C-terminal activated derivative of the unreacted N-terminal protected amino acid or peptide can be quickly inactivated. This allows the peptide to be produced with fewer steps and in a short time.
[0053] The capping agent used in this step may be prepared by, for example, purchasing a commercially available product.
[0054] This step can be carried out by introducing a reaction mixture containing the N-terminal and C-terminal protected peptide extended to the N-terminus side and a solution containing a capping agent in a solvent into a flow reactor at a predetermined flow rate. The solvent can be the same as the solvent exemplified in the explanation of the C-terminus activation step. The reaction mixture containing the N-terminal and C-terminal protected peptide extended to the N-terminus side usually contains the solvent used in the condensation step. The solution containing the capping agent preferably contains the hydrophilic organic solvent exemplified above as a solvent, and more preferably contains DMSO as a solvent. By using the solvent exemplified above, the solution containing the capping agent can be successfully prepared.
[0055] The solvent used in this step may be prepared by, for example, purchasing a commercially available product.
[0056] In the present embodiment, in the reaction mixture containing the N-terminal and C-terminal protected peptide extended to the N-terminus, the concentration of the N-terminal and C-terminal protected peptide extended to the N-terminus is preferably in the range of 0.01 to 1.0 mol / L, more preferably in the range of 0.05 to 0.3 mol / L. The concentration of the N-terminal and C-terminal protected peptide extended to the N-terminus may vary within the above range depending on the reaction yield in the condensation step. In the solution containing the capping agent, the amount of the capping agent is preferably in the range of 0.5 to 20 molar equivalents relative to the C-terminal protected amino acid or peptide, more preferably in the range of 0.5 to 2.0 molar equivalents. If the amount or concentration of the component is less than the lower limit, the yield of the reaction with the capping agent may decrease. In addition, if the amount or concentration of the component exceeds the upper limit, these components may not be sufficiently dissolved in the solvent and may precipitate in the flow reactor. If the components precipitate, the flow reactor may become clogged. By carrying out this step in the amount or concentration within the above range, an activated derivative can be formed with high efficiency, and the peptide can be produced in a short time without causing clogging of the flow reactor.
[0057] In the case of the embodiment, the flow rate of the reaction mixture containing the N-terminal and C-terminal protected peptide extended to the N-terminus side is preferably in the range of 0.3 to 300 mL / min, more preferably in the range of 1.5 to 60 mL / min. The flow rate of the reaction mixture containing the N-terminal and C-terminal protected peptide extended to the N-terminus side may vary within the above range depending on the flow rate of each solution in the condensation step. The flow rate of the solution containing the capping agent is preferably in the range of 0.05 to 50 mL / min, more preferably in the range of 0.25 to 10 mL / min. If the flow rate is less than the lower limit, the production time of the peptide by the method of this aspect may be extended. Also, if the flow rate exceeds the upper limit, the efficiency of the reaction with the capping agent may be reduced. By carrying out this step at a flow rate in the above range, the peptide can be produced in a short time.
[0058] In this step, the temperature for the reaction between the unreacted N-terminal protected amino acid or the C-terminal activated derivative of the peptide and the capping agent in the flow reactor is preferably in the range of 0 to 100°C, more preferably in the range of 20 to 60°C. If the reaction temperature is below the lower limit, the efficiency of the reaction may decrease. If the reaction temperature exceeds the upper limit, by-products may be produced. By carrying out this step at a temperature within the above range, the desired peptide can be produced in high yield.
[0059] In this step, the time for the reaction of the unreacted N-terminal protected amino acid or the C-terminal activated derivative of the peptide with the capping agent in the flow reactor is preferably in the range of 1 second to 60 minutes, and more preferably in the range of 10 to 60 seconds. If the reaction time is less than the lower limit, the efficiency of the reaction may decrease. If the reaction time exceeds the upper limit, by-products may be generated. By carrying out this step for a time in the above range, the desired peptide can be produced in high yield.
[0060] By carrying out this step under the above-mentioned conditions, the unreacted N-terminal protected amino acid or C-terminal activated derivative of the peptide can be reacted with the capping agent in the flow reactor to inactivate the unreacted N-terminal protected amino acid or C-terminal activated derivative of the peptide, thereby substantially suppressing the formation of by-products caused by the unreacted N-terminal protected amino acid or C-terminal activated derivative of the peptide, and producing the desired peptide in high yield.
[0061] [1-4. N-terminal deprotection step (S4)] This step involves introducing an N-terminally and C-terminally protected peptide extended toward the N-terminus and a deprotecting agent for the N-terminus protecting group into a flow reactor, and deprotecting the N-terminus protecting group in the flow reactor to form a C-terminus protected peptide extended toward the N-terminus.
[0062] The N-terminally and C-terminally protected peptide extended on the N-terminus side used in this step is obtained in the condensation step or capping step described above.
[0063] The deprotecting agent for the N-terminal protecting group used in this step can be appropriately selected depending on the N-terminal protecting group of the N-terminal and C-terminal protected peptide extended to the N-terminal side. For example, when the N-terminal protecting group is a group that is deprotected by a base such as an Fmoc group, the deprotecting agent is preferably an organic base such as 1,8-diazabicyclo[5.4.0]-7-undecene (DBU) or piperidine, and more preferably DBU. When the N-terminal protecting group is a group that is deprotected by an acid such as a Boc group, the deprotecting agent is preferably an acid such as trifluoroacetic acid (TFA) or hydrogen chloride dissolved in an organic solvent, and more preferably TFA. When the N-terminal protecting group is a group that is deprotected by catalytic reduction such as a Cbz group, the deprotecting agent is preferably palladium / carbon (Pd / C) or Pd(OH) 2 The catalyst is preferably palladium / carbon or the like, and more preferably palladium / carbon. When the N-terminal protecting group is a group that is deprotected by a nucleophilic substitution reaction using a palladium catalyst such as an Alloc group, the deprotecting agent is preferably a palladium(0) catalyst, and more preferably tetrakis(triphenylphosphine)palladium(0). By carrying out this step using the deprotecting agents exemplified above, the N-terminal protecting group can be rapidly deprotected.
[0064] In this step, when a highly reactive deprotection by-product is formed by the deprotection reaction of the N-terminal protecting group, it is preferable to carry out the deprotection reaction in the presence of a trapping agent that traps the deprotection by-product. The trapping agent can be appropriately selected depending on the N-terminal protecting group of the N-terminal and C-terminal protected peptide extended to the N-terminal side. For example, when the N-terminal protecting group is an Fmoc group, the trapping agent is preferably a base such as a mercaptoalkanesulfonate or piperidine that can trap the deprotection by-product dibenzofulvene, and more preferably 3-mercapto-1-propanesulfonic acid sodium salt (3-MPSNa). When the N-terminal protecting group is a Boc group, the trapping agent is preferably anisole, thioanisole, dimethylsulfide, thiophenol, or the like. By carrying out this step using the deprotection agent exemplified above, the highly reactive deprotection by-product can be trapped and inactivated. This allows the peptide to be produced in a high yield.
[0065] In the case of the above embodiment, the scavenger may be introduced into the flow reactor together with or separately from the N-terminal and C-terminal protected peptides extended to the N-terminus and the deprotecting agent for the N-terminus protecting group. It is preferable to introduce the deprotecting agent for the N-terminus protecting group and the scavenger separately into the flow reactor, more preferably to introduce a solution containing the N-terminus and C-terminus protected peptide extended to the N-terminus side and a solution containing the scavenger together or separately into the flow reactor, and then introduce a solution containing the deprotecting agent for the N-terminus protecting group into the flow reactor, and it is even more preferable to introduce a solution containing the N-terminus and C-terminus protected peptide extended to the N-terminus side and a solution containing the scavenger separately into the flow reactor, and then introduce a solution containing the deprotecting agent for the N-terminus protecting group into the flow reactor. By introducing each solution into the flow reactor in the above order, the deprotection by-product can be efficiently captured.
[0066] The deprotecting agent and the scavenger used in this step may be prepared by, for example, purchasing a commercially available product.
[0067] This step can be carried out by introducing a reaction mixture containing an N-terminal and C-terminal protected peptide extended to the N-terminus side, a solution containing a deprotecting agent in a solvent, and optionally a solution containing a scavenger in a solvent, into a flow reactor at a predetermined flow rate. The solvent can be the same as the solvent exemplified in the explanation of the C-terminal activation step. The reaction mixture containing an N-terminal and C-terminal protected peptide extended to the N-terminus side usually contains the solvent used in the condensation step or capping step. The solution containing the deprotecting agent and the solution containing the scavenger preferably contain the hydrophilic organic solvent exemplified above as a solvent, and more preferably contain DMSO as a solvent. By using the solvent exemplified above, the solution containing the deprotecting agent and the solution containing the scavenger can be successfully prepared.
[0068] The solvent used in this step may be prepared by, for example, purchasing a commercially available product.
[0069] In this embodiment, as the solution containing the N-terminally and C-terminally protected peptide extended to the N-terminus, it is preferable to use the reaction mixture containing the N-terminally and C-terminally protected peptide extended to the N-terminus obtained in the condensation step or capping step as it is, and it is more preferable to use the reaction mixture containing the N-terminally and C-terminally protected peptide extended to the N-terminus obtained in the capping step as it is. By using the reaction mixture containing the N-terminally and C-terminally protected peptide extended to the N-terminus obtained in the capping step, the formation of by-products due to unreacted N-terminally protected amino acids or C-terminal activated derivatives of the peptide can be substantially suppressed, and the desired peptide can be produced in high yield.
[0070] In the present embodiment, in the reaction mixture containing the N-terminal and C-terminal protected peptide extended to the N-terminus, the concentration of the N-terminal and C-terminal protected peptide extended to the N-terminus is preferably in the range of 0.01 to 1.0 mol / L, more preferably in the range of 0.05 to 0.3 mol / L. The concentration of the N-terminal and C-terminal protected peptide extended to the N-terminus may vary within the above range depending on the reaction yield in the condensation step or the capping step. In the solution containing the deprotecting agent, the amount of the deprotecting agent is preferably in the range of 1 to 100 molar equivalents relative to the C-terminal protected amino acid or peptide, more preferably in the range of 1 to 10 molar equivalents. In the solution containing the scavenger, the concentration of the scavenger is preferably in the range of 1 to 10 molar equivalents relative to the C-terminal protected amino acid or peptide, more preferably in the range of 1 to 3 molar equivalents. If the amount or concentration of the component is less than the lower limit, the yield of the deprotection reaction may decrease. Furthermore, if the amount or concentration of the components exceeds the upper limit, these components may not be sufficiently dissolved in the solvent and may precipitate in the flow reactor. If the components precipitate, the flow reactor may become clogged. By carrying out this step with the amount or concentration in the above range, the N-terminal protecting group can be deprotected with high efficiency, and the peptide can be produced in a short time without causing clogging of the flow reactor.
[0071] In the case of the above embodiment, the flow rate of the reaction mixture containing the N-terminal and C-terminal protected peptide extended to the N-terminal side is preferably in the range of 0.35 to 350 mL / min, more preferably in the range of 1.75 to 70 mL / min. The flow rate of the reaction mixture containing the N-terminal and C-terminal protected peptide extended to the N-terminal side may vary within the above range depending on the flow rate of each solution in the condensation step or the capping step. The flow rate of the solution containing the deprotecting agent is preferably in the range of 0.1 to 100 mL / min, more preferably in the range of 0.5 to 20 mL / min. The flow rate of the solution containing the scavenger is preferably in the range of 0.05 to 50 mL / min, more preferably in the range of 0.25 to 10 mL / min. If the flow rate is less than the lower limit, the production time of the peptide by the method of this aspect may be longer. If the flow rate exceeds the upper limit, the efficiency of the deprotection reaction may be reduced. By carrying out this step at a flow rate within the above range, the peptide can be produced in a short period of time.
[0072] In this step, the temperature of the deprotection reaction in the flow reactor is preferably in the range of 0 to 100°C, and more preferably in the range of 5 to 60°C. If the temperature of the deprotection reaction is below the lower limit, the efficiency of the reaction may decrease. If the temperature of the deprotection reaction exceeds the upper limit, by-products may be produced. By carrying out this step at a temperature in the above range, the N-terminal protecting group can be rapidly deprotected, and the desired peptide can be produced in high yield.
[0073] In this step, the time for the deprotection reaction in the flow reactor is preferably in the range of 1 second to 60 minutes, and more preferably in the range of 10 to 60 seconds. If the time for the deprotection reaction is less than the lower limit, the efficiency of the reaction may decrease. If the time for the deprotection reaction exceeds the upper limit, by-products may be generated. By carrying out this step for a time in the above range, the N-terminal protecting group can be rapidly deprotected, and the desired peptide can be produced in high yield.
[0074] By carrying out this step under the above conditions, the N-terminal protecting group can be deprotected in the flow reactor to form a C-terminal protected peptide extended to the N-terminus, thereby enabling the desired peptide to be produced in high yield by rapidly deprotecting the N-terminal protecting group.
[0075] [1-5. Extraction process (S5)] This step involves mixing a reaction mixture containing a C-terminally protected peptide extended on the N-terminus side with an aqueous phase, extracting the C-terminally protected peptide extended on the N-terminus side into the organic phase, and separating the organic phase from the aqueous phase.
[0076] As described above, the C-terminal protected peptide extended to the N-terminus has a tag protecting group as a protecting group for the C-terminal carboxyl group, which reduces the polarity so that the peptide can be separated and purified by two-phase separation into an organic phase and an aqueous phase. Therefore, by mixing a reaction mixture containing a C-terminal protected peptide extended to the N-terminus with an aqueous phase, the mixture is separated into two phases, an organic phase containing the peptide and an aqueous phase. Since the unreacted raw materials used in each step described above and by-products formed by the reaction are transferred to the aqueous phase, the C-terminal protected peptide extended to the N-terminus can be extracted by separating the organic phase from the mixture.
[0077] The aqueous phase used in this step may contain, in addition to water, a salt such as sodium chloride, sodium carbonate, potassium bicarbonate, or sodium bicarbonate, or an acid such as hydrochloric acid or sulfuric acid, if desired. Furthermore, the aqueous phase may contain the hydrophilic organic solvent exemplified above, if desired. By including the salt, acid, and / or hydrophilic organic solvent exemplified above in the aqueous phase, the efficiency of extraction of the C-terminal protected peptide extended toward the N-terminus can be improved.
[0078] The salt, acid and hydrophilic organic solvent used in this step may be prepared by, for example, purchasing commercially available products.
[0079] This step may be carried out by a flow synthesis method or a batch process.
[0080] When this step is carried out by a flow synthesis method, the reaction mixture containing the C-terminal protected peptide extended to the N-terminus side and the aqueous phase are introduced into a flow reactor at a predetermined flow rate, and the C-terminal protected peptide extended to the N-terminus side is extracted in the flow reactor. In the case of this embodiment, the flow rate at which the reaction mixture containing the C-terminal protected peptide extended to the N-terminus side is introduced into the flow reactor is preferably in the range of 0.4 to 400 mL / min, more preferably in the range of 2.5 to 100 mL / min. The flow rate of the reaction mixture containing the C-terminal protected peptide extended to the N-terminus side may vary within the above range depending on the flow rate of each solution in the deprotection step. The flow rate at which the aqueous phase is introduced into the flow reactor is preferably in the range of 0.1 to 1600 mL / min, more preferably in the range of 1.25 to 200 mL / min. If the flow rate is less than the lower limit, the production time of the peptide by the method of this embodiment may be longer. If the flow rate exceeds the upper limit, the extraction efficiency of the C-terminal protected peptide extended to the N-terminus side may decrease. By carrying out this step at a flow rate within the above range, the peptide can be produced in a short period of time.
[0081] In the case of the above embodiment, the temperature of extraction in the flow reactor is preferably in the range of 5 to 60°C, more preferably in the range of 10 to 30°C. If the temperature of extraction is below the lower limit, the efficiency of extraction may decrease. If the temperature of extraction is above the upper limit, by-products may be generated. By carrying out this step at a temperature within the above range, the desired peptide can be produced in high yield.
[0082] In the case of the above embodiment, the extraction time in the flow reactor is preferably in the range of 30 seconds to 24 hours, and more preferably in the range of 30 seconds to 30 minutes. If the extraction time is less than the lower limit, the efficiency of the extraction may decrease. If the extraction time exceeds the upper limit, by-products may be generated. By carrying out this step for a time in the above range, the desired peptide can be produced in high yield.
[0083] When this step is carried out by batch treatment, the reaction mixture containing the C-terminally protected peptide extended on the N-terminus side and the aqueous phase are introduced into a vessel, and the C-terminally protected peptide extended on the N-terminus side is extracted in the vessel.
[0084] In the case of the above embodiment, the temperature of extraction in the vessel is preferably in the range of 5 to 60°C, more preferably in the range of 10 to 30°C. If the temperature of extraction is below the lower limit, the efficiency of extraction may decrease. If the temperature of extraction is above the upper limit, by-products may be generated. By carrying out this step at a temperature within the above range, the desired peptide can be produced in high yield.
[0085] In the case of the above embodiment, the extraction time in the vessel is preferably in the range of 0.5 seconds to 24 hours, more preferably in the range of 1 second to 30 minutes. If the extraction time is less than the lower limit, the efficiency of the extraction may decrease. If the extraction time exceeds the upper limit, by-products may be generated. By carrying out this step for a time in the above range, the desired peptide can be produced in high yield.
[0086] By carrying out this step under the above conditions, the desired peptide can be produced in a high yield with fewer steps and in a short period of time.
[0087] The extract containing the C-terminal protected peptide extended on the N-terminus side obtained in this step can be used as it is or in a concentrated state as the C-terminal protected amino acid or peptide in the condensation step, thereby allowing the peptide chain to be continuously extended to produce a peptide having a desired amino acid sequence.
[0088] [1-6. C-terminal deprotection step (S6)] This step involves reacting the C-terminally protected peptide extended on the N-terminus side obtained in the extraction step with a C-terminal deprotecting agent to deprotect the C-terminal tag protecting group and form a peptide extended on the N-terminus side.
[0089] This step can be carried out by reacting the extract containing the C-terminal protected peptide extended on the N-terminal side obtained in the extraction step, either as is or after concentration, with a deprotecting agent for the C-terminal tag protecting group and, if desired, a deprotecting agent for the side chain protecting group. In this embodiment, the deprotecting agent for the C-terminal tag protecting group and the deprotecting agent for the side chain protecting group can be appropriately selected depending on the C-terminal tag protecting group and the side chain protecting group used.
[0090] By carrying out this step under the above conditions, the C-terminal tag protecting group and the side chain protecting group can be deprotected to obtain the desired peptide in a free form, thereby enabling the production of the desired peptide in high yield with fewer steps and in a short time.
[0091] <2. Peptide manufacturing equipment> Another aspect of the present invention relates to an apparatus for producing a peptide. By using the apparatus of this aspect, a desired peptide can be produced in high yield with a small number of steps in a short time.
[0092] The device of this embodiment comprises: a C-terminal activation means having a flow reactor and a raw material introduction member for introducing an N-terminal protected amino acid or peptide whose N-terminal amino group is protected by an N-terminal protecting group, and a C-terminal activating agent into the flow reactor, which activates the C-terminal carboxyl group of the N-terminal protected amino acid or peptide in the flow reactor to form a C-terminal activated derivative of the N-terminal protected amino acid or peptide; a condensation means having a flow reactor and a raw material introducing member for introducing into the flow reactor a C-terminal activated derivative of an N-terminal protected amino acid or peptide, and a C-terminal protected amino acid or peptide whose C-terminal carboxyl group is protected by a tag protecting group, the condensation means comprising: a flow reactor; and a raw material introducing member for introducing into the flow reactor a C-terminal activated derivative of an N-terminal protected amino acid or peptide, and a C-terminal protected amino acid or peptide whose C-terminal carboxyl group is protected by a tag protecting group, the N-terminal protected amino acid or peptide being condensed to the N-terminal side of the C-terminal protected amino acid or peptide in the flow reactor to form an N-terminal and C-terminal protected peptide extended to the N-terminal side; N-terminal deprotection means, which has a flow reactor and a raw material introduction member for introducing an N-terminal and C-terminal protected peptide extended to the N-terminal side and a deprotecting agent for the N-terminal protecting group into the flow reactor, for deprotecting the N-terminal protecting group in the flow reactor to form a C-terminal protected peptide extended to the N-terminal side; and an extraction means having a mixing member for mixing a reaction mixture containing a C-terminal protected peptide extended on the N-terminus side with an aqueous phase, for mixing the reaction mixture containing the C-terminal protected peptide extended on the N-terminus side with the aqueous phase to extract the C-terminal protected peptide extended on the N-terminus side into an organic phase; Includes.
[0093] The device of this embodiment may optionally include: a capping means having a flow reactor and a raw material introduction member for introducing a reaction mixture containing an N-terminally and C-terminally protected peptide extended on the N-terminal side, and a capping agent having an amino group into the flow reactor, which reacts an unreacted C-terminal activated derivative of an N-terminally protected amino acid or peptide with the capping agent in the flow reactor to inactivate the C-terminal activated derivative; It may further include.
[0094] A schematic diagram showing one embodiment of the device of this aspect is shown in Figure 2. As shown in Figure 2, in the device of this aspect, the C-terminal activation means, condensation means, capping means, and N-terminal deprotection means each have a flow reactor and a raw material introduction member. The flow reactor usually has at least two or more inlet flow channels 11, 21, 31, 41a, 41b, mixers 12, 22, 32, 42a, 42b that mix the reaction liquid flowing in from the two or more inlet flow channels 11, 21, 31, 41a, 41b, and one or more outlet flow channels 13, 23, 33, 43a, 43b that discharge the reaction liquid mixed in the mixers 12, 22, 32, 42a, 42b. The inlet flow channels and the outlet flow channels are preferably pipes made of materials described below. The raw material introduction member usually has at least pumps 14a, 14b, 24, 34, 44a, 44b for feeding the raw material. The pump usually has a storage tank for storing the raw material, a liquid feeding member, and a flow path connecting the storage tank and the liquid feeding member. Examples of the pump include a syringe pump, a diaphragm pump, and a high performance liquid chromatograph (HPLC) pump. For example, when the pump is a syringe pump, it is not necessary to have a storage tank as a separate member because the raw material can be stored in the cylinder of the syringe. In the condensation means, capping means, and N-terminal deprotection means, it is preferable to use one or more outflow flow paths 13, 23, 33, 43a, 43b for discharging the reaction solution containing the product obtained in the previous step as the raw material introduction member for introducing the product.
[0095] In one embodiment, the extraction means has an extraction member, a raw material introduction member, and an aqueous phase introduction member. The extraction member usually has at least two or more inflow channels 43b, 51, a mixer 52 that mixes the reaction liquid and the aqueous phase flowing in from the two or more inflow channels 43b, 51, one or more outflow channels 53 that discharge the mixed phase of the reaction liquid and the aqueous phase mixed in the mixer 52, a phase separation member 58 that separates the mixed phase of the reaction liquid and the aqueous phase flowing in from the one or more outflow channels 53 into an organic phase and an aqueous phase, and one or more outflow channels 63 that discharge the organic phase separated by the phase separation member 58. The inflow channels and the outflow channels are preferably pipes made of a material described below. The aqueous phase introduction member usually has at least a pump 54 for sending the aqueous phase. The pump usually has a storage tank for storing the raw material, a liquid delivery member, and a flow path connecting the storage tank and the liquid delivery member. Examples of the pump include a syringe pump, a diaphragm pump, and an HPLC pump. For example, when the pump is a syringe pump, the raw material can be stored in the cylinder of the syringe, so there is no need to have a storage tank as a separate member. In the extraction means, it is preferable to use one or more outflow flow channels 43b that discharge the reaction liquid containing the product obtained in the preceding N-terminal deprotection means as a raw material introduction member for introducing the product. In that case, it is preferable to have a pressure adjustment means for adjusting the pressure of the outflow liquid in the middle of the outflow flow channel 43b from the N-terminal deprotection means. In addition, the extraction means may have two or more combinations of the extraction member, raw material introduction member, and aqueous phase introduction member described above.
[0096] The device of this embodiment may optionally include: A circulation means for circulating the C-terminal protected peptide extended on the N-terminal side obtained by the extraction means into a raw material introduction member for the condensation step: It may further include.
[0097] In this embodiment, the circulation inflow means has at least a circulation inflow flow path 61 for circulating the C-terminal protected peptide extended to the N-terminus side obtained by the extraction means to the raw material introduction member of the condensation step, and a pump 64 for feeding the C-terminal protected peptide extended to the N-terminus side. The circulation inflow flow path is preferably a pipe made of a material described below. The pump usually has a storage tank for storing the C-terminal protected peptide extended to the N-terminus side, a liquid delivery member, and a flow path connecting the storage tank and the liquid delivery member. Examples of the pump include a syringe pump, a diaphragm pump, and an HPLC pump. For example, when the pump is a syringe pump, the C-terminal protected peptide extended to the N-terminus side can be stored in the cylinder of the syringe, so there is no need to have a storage tank as a separate member. By including the circulation inflow means in the device of this embodiment, it is possible to continuously elongate the peptide chain and produce a peptide having a desired amino acid sequence.
[0098] In the apparatus of this embodiment, at least any one of the C-terminal activation means, condensation means, capping means, N-terminal deprotection means, extraction means, and circulation inflow means preferably has a temperature adjustment device for adjusting the temperature of the flow reactor, the raw material introduction member, and / or the water bath introduction member. The temperature adjustment device is preferably used to adjust the temperature of, for example, the inflow flow path, the outflow flow path, the circulation inflow flow path, the mixer, the phase separation member, the pump storage tank, and / or the pump flow path. By having the temperature adjustment device, the temperature of the flow reactor, the raw material introduction member, and / or the water bath introduction member can be adjusted based on the physical property detected by the physical property detection member described below.
[0099] In the device of this embodiment, at least one of the C-terminal activation means, condensation means, capping means, N-terminal deprotection means, extraction means and circulation inflow means preferably has at least one property detection member for detecting the physical properties of the raw materials and the reaction liquid. The property detection member is preferably at least one member selected from the group consisting of a pressure gauge, a flow meter and a thermometer. The property detection member is preferably disposed midway through the inflow channel, the outflow channel and / or the circulation inflow channel. By having at least one property detection member, it is possible to detect the physical properties of the raw materials and the reaction liquid to check the progress of the reaction and adjust the reaction conditions based on the physical properties.
[0100] At least one of the C-terminal activation means, condensation means, capping means, N-terminal deprotection means, extraction means, and circulation inflow means preferably has at least one compound detection member for detecting compounds contained in the raw material and the reaction solution. The compound detection member is preferably at least one member selected from the group consisting of an ultraviolet-visible spectrometer, a photodiode array detector, a fluorescence detector, a differential refractive index detector, an electrical conductivity detector, an evaporative light scattering detector, an infrared spectrometer, a near-infrared spectrometer, a nuclear magnetic resonance device, and a mass spectrometer. The compound detection member is preferably disposed midway through the inflow channel and / or the outflow channel. In this embodiment, at least one of the C-terminal activation means, condensation means, capping means, N-terminal deprotection means, extraction means, and circulation inflow means preferably further has a compound separation member for separating compounds detected by the compound detection member. In this case, the compound separation member is usually disposed on the front side (i.e., upstream side) of the compound detection member in the flow channel of the raw material, the reaction solution, etc. By having at least one compound detection member, it is possible to detect compounds contained in the raw material and the reaction solution and confirm the progress of the reaction.
[0101] At least one of the C-terminal activation means, condensation means, capping means, N-terminal deprotection means, extraction means, and circulation inflow means preferably has at least one outlet for sampling the reaction solution, etc. The outlet is preferably disposed in at least one outflow channel in at least one of the means. By having at least one outlet, the progress of the reaction can be confirmed by sampling the reaction solution, etc.
[0102] A schematic diagram showing another embodiment of the device of this aspect is shown in FIG. 3. As shown in FIG. 3, the device of this embodiment may include a C-terminal activation means, a condensation means, a capping means, an N-terminal deprotection means, a two-stage extraction means, and a circulation inflow means. The C-terminal activation means at least includes a pump 14a for feeding an N-terminal protected amino acid or peptide, a pump 14b for feeding a C-terminal activator, two inflow channels 11 for feeding these raw materials, a mixer 12 for mixing the reaction liquids flowing in from the two inflow channels 11, and an outflow channel 13 for discharging the reaction liquid mixed in the mixer 12. The condensation means at least includes a pump 24 for feeding a C-terminal protected amino acid or peptide, an inflow channel 21 for feeding the C-terminal protected amino acid or peptide, a mixer 22 for mixing the reaction liquids flowing in from the outflow channel 13 from the C-terminal activation means and the inflow channel 21, and an outflow channel 23 for discharging the reaction liquid mixed in the mixer 22. The capping means has at least a pump 34 for feeding a capping agent, an inflow flow path 31 for feeding the capping agent, a mixer 32 for mixing the reaction liquid flowing in from the outflow flow path 23 from the condensation means and the inflow flow path 31, and an outflow flow path 33 for feeding the reaction liquid mixed in the mixer 32. The N-terminal deprotection means has at least a pump 44b for feeding a deprotection agent for the N-terminal protecting group, an inflow flow path 41b for feeding the deprotection agent for the N-terminal protecting group, a mixer 42b for mixing the reaction liquid flowing in from the outflow flow path from the capping means and the inflow flow path 41b, and an outflow flow path 43b for feeding the reaction liquid mixed in the mixer 42b. The N-terminal deprotection means preferably has, upstream of the mixer 42b, a pump 44a for delivering a scavenger that captures deprotection by-products, an inflow flow path 41a for introducing the scavenger, a mixer 42a for mixing the reaction liquid flowing in from the outflow flow path 33 from the capping means and the inflow flow path 41a, and an outflow flow path 43a for discharging the reaction liquid mixed in the mixer 42a.The extraction means preferably has pumps 54a, 54b for sending the aqueous phase, inflow channels 51a, 51b for introducing the aqueous phase, mixers 52a, 52b for mixing the reaction liquid introduced from the outflow channel 43b from the N-terminal deprotection means and the aqueous phase introduced from the inflow channels 51a, 51b, outflow channels 53a, 53b for discharging the mixed phase of the reaction liquid and the aqueous phase mixed in the mixers 52a, 52b, phase separation members 58a, 58b for separating the mixed phase of the reaction liquid and the aqueous phase mixed in the mixers 52a, 52b into an organic phase and an aqueous phase, and one or more outflow channels 63 for discharging the organic phase separated by the phase separation members 58a, 58b. The extraction means preferably has a pressure adjustment means 59 for adjusting the pressure of the effluent in the middle of the outflow channel 43b from the N-terminal deprotection means. The circulation inflow means has at least a circulation inflow flow path 61 for circulating the C-terminal protected peptide extended on the N-terminal side obtained in the extraction means into the raw material introduction member of the condensation step, and a pump 64 for feeding the C-terminal protected peptide extended on the N-terminal side. The C-terminal activation means, condensation means, capping means, and N-terminal deprotection means preferably have a temperature control device for controlling the temperature of the flow reactor, raw material introduction member, and / or water bath introduction member. At least one pressure gauge 81 and at least one flow meter 82 are preferably provided in the inflow flow paths of the C-terminal activation means, condensation means, capping means, N-terminal deprotection means, and extraction means. In addition, at least one thermometer 83 is preferably provided in the outflow flow path of the condensation means and the outflow flow path of the N-terminal deprotection means.
[0103] In the apparatus of this embodiment, the materials of the members constituting the flow reactor and the raw material introduction member are not limited, but examples thereof include metals, fluororesins (e.g., polytetrafluoroethylene (PTFE), perfluoroalkoxyalkane (PFA), ethylene tetrafluoroethylene copolymer (ETFE), and perfluoroethylene propene copolymer (FEP)), polyether ether ketone (PEEK), polyethylene (PE), polypropylene (PP), glass, and silicon. By using a flow reactor and a raw material introduction member made of the above materials, it is possible to substantially avoid the influence of solvents and the like. The inflow channel and the outflow channel are preferably tubes made of the above materials commonly used in the technical field, and more preferably PTFE tubes. The mixer, syringe, and pump are preferably made of the above materials commonly used in the technical field. The inner diameters of the inflow channel, the outflow channel, and the mixer are preferably 5 mm or less, and more preferably in the range of 0.25 to 2 mm. By using a flow reactor made of members having inner diameters in the above range, the apparatus of this embodiment can be applied to the peptide production method of one embodiment of the present invention carried out in a microflow system.
[0104] In the device of this embodiment, the extraction means has a mixing member for mixing the reaction mixture containing the C-terminal protected peptide extended to the N-terminus side and the aqueous phase. The mixing member can be appropriately selected depending on the embodiment of the extraction. For example, when the extraction is performed by a flow synthesis method, the flow reactor described above can be used as the mixing member. Alternatively, when the extraction is performed by a batch process, various shapes of containers made of glass, metal, or plastic that are commonly used in the technical field can be used as the mixing member.
[0105] As described in detail above, the peptide production method and production apparatus of one embodiment of the present invention can produce a desired peptide with a high yield, using fewer steps and in a shorter period of time, compared to the methods and apparatus of the prior art. EXAMPLES
[0106] Hereinafter, the present invention will be described in more detail with reference to examples. However, the technical scope of the present invention is not limited to these examples.
[0107] <I: Peptide production apparatus> As shown in FIG. 2, a peptide production apparatus having a plurality of flow reactors (hereinafter also referred to as "production apparatus 1") was fabricated using a polytetrafluoroethylene (PTFE) tube (inner diameter 0.8 mm, outer diameter 1.59 mm), a T-shaped mixer (inner diameter 0.25 mm, manufactured by Mitsuyuki Seiki Co., Ltd.), a syringe pump (PHD ULTRA, manufactured by Harvard Apparatus), and a syringe with a capacity of 10 to 50 ml (SGE syringe, manufactured by TRAJAN).
[0108] As shown in FIG. 3, a peptide production apparatus having a plurality of flow reactors (hereinafter also referred to as "production apparatus 2") was fabricated using a polytetrafluoroethylene (PTFE) tube (inner diameter 1.59 mm, outer diameter 1 / 8 inch), a T-shaped mixer (inner diameter 0.5 mm, manufactured by Idex), a Y-shaped mixer (inner diameter 1.5 mm, manufactured by Idex), an HPLC pump (PU-4086, manufactured by JASCO Corporation), a diaphragm pump (QI-30, manufactured by Tacmina), and a back pressure regulator (BPR-1000, manufactured by Zaiput). A flow meter and a pressure gauge were installed in the flow path between the pump for feeding each reagent and the T-shaped mixer to measure the flow rate and pressure during synthesis. Thermometers were installed in the outflow channels of the condensation means and the N-terminal deprotection means to measure the temperature of the reaction solution. At least one compound detection member such as a near-infrared spectrometer was installed in the present apparatus near the capping means and / or the N-terminal deprotection means to detect the disappearance of the raw material and / or the generation of the reaction product. Further, a loop and a valve for sampling the reaction solution and the like were installed in the outflow channels of the capping means and / or the N-terminal deprotection means of the present apparatus, and each reaction solution and the like could be sampled and analyzed.
[0109] <II: Peptide production by the method of the present invention> [II-1: Synthesis of C-terminal protected amino acid] According to the method described in WO 2017 / 038650, the C-terminal carboxyl group of Fmoc-Arg(Pbf)-OH was protected with a tag protecting group of a monovalent group (a free group resulting from the removal of the hydrogen atom of a hydroxyl group) derived from the compound represented by the following formula (TIPS2-OH), to synthesize the C-terminal protected amino acid, H-Arg(Pbf)-O-TIPS2. [ka]
[0110] [II-2: Synthesis of H-Arg(Pbf)-Arg(Pbf)-O-TIPS2 (Example 1)] The following reaction was carried out using the production apparatus 1. Solution 1 (DMF solution containing 0.433 mol / L of Fmoc-Arg(Pbf)-OH, 0.043 mol / L of N,N-dimethylbenzylamine (DMBA), and 0.433 mol / L of DIEA) was delivered at a flow rate of 1.2 mL / min, and solution 2 (cyclopentyl methyl ether (CPME) solution containing 0.255 mol / L of IBCF) was delivered at a flow rate of 2.0 mL / min, mixed in a T-shaped mixer, and reacted for 5 seconds in a PTFE tube to produce a C-terminal activated derivative of the N-terminal protected amino acid (C-terminal activation step). Next, a solution containing 0.16 mol / L of this C-terminal activated derivative was fed at a flow rate of 3.2 mL / min, and solution 3 (a mixed solution of DMF and CPME containing 0.200 mol / L of H-Arg(Pbf)-O-TIPS2) was fed at a flow rate of 2.0 mL / min, mixed in a T-shaped mixer, and reacted for 30 seconds in a PTFE tube to perform a condensation reaction (condensation step). Next, this condensation reaction solution was fed at a flow rate of 5.2 mL / min, and solution 4 (a DMSO solution containing 1.04 mol / L of AEE) was fed at a flow rate of 0.5 mL / min, mixed in a T-shaped mixer, and reacted for 30 seconds in a PTFE tube to perform a capping reaction (capping step). Next, this capping reaction solution was fed at a flow rate of 5.7 mL / min, and solution 5 (DMSO solution containing 0.81 mol / L of 3-MPSNa) was fed at a flow rate of 1.2 mL / min, and mixed in a T-shaped mixer. Then, this mixture was fed at a flow rate of 6.9 mL / min, and solution 6 (DMSO solution containing 4.86 mol / L of DBU) was fed at a flow rate of 0.5 mL / min, and mixed in a T-shaped mixer. The mixture was reacted for 30 seconds in a PTFE tube, and the deprotection reaction of the Fmoc group was performed (N-terminal deprotection step). The reaction solution flowing out of the PTFE tube was sampled and analyzed by LCMS (LCMS analysis result: m / z = 1611). The C-terminal activation step to the N-terminal deprotection step were performed at 60 °C.
[0111] [II-3: Synthesis of H-Phe-Arg(Pbf)-O-TIPS2 (Example 2)] The following reaction was carried out using the production apparatus 1. Solution 1 (DMF solution containing 0.433 mol / L of Fmoc-Phe-OH, 0.043 mol / L of DMBA, and 0.433 mol / L of DIEA) was delivered at a flow rate of 1.2 mL / min, and solution 2 (CPME solution containing 0.255 mol / L of IBCF) was delivered at a flow rate of 2.0 mL / min, mixed in a T-shaped mixer, and reacted for 5 seconds in a PTFE tube to produce a C-terminal activated derivative of the N-terminal protected amino acid (C-terminal activation step). Next, a solution containing 0.16 mol / L of this C-terminal activated derivative was fed at a flow rate of 3.2 mL / min, and solution 3 (a mixed solution of DMF and CPME containing 0.200 mol / L of H-Arg(Pbf)-O-TIPS2) was fed at a flow rate of 2.0 mL / min, mixed in a T-shaped mixer, and reacted for 30 seconds in a PTFE tube to perform a condensation reaction (condensation step). Next, this condensation reaction solution was fed at a flow rate of 5.2 mL / min, and solution 4 (a DMSO solution containing 1.04 mol / L of AEE) was fed at a flow rate of 0.5 mL / min, mixed in a T-shaped mixer, and reacted for 30 seconds in a PTFE tube to perform a capping reaction (capping step). Next, this capping reaction solution was fed at a flow rate of 5.7 mL / min, and solution 5 (DMSO solution containing 0.81 mol / L of 3-MPSNa) was fed at a flow rate of 1.2 mL / min, and mixed in a T-shaped mixer. Then, this mixture was fed at a flow rate of 6.9 mL / min, and solution 6 (DMSO solution containing 4.86 mol / L of DBU) was fed at a flow rate of 0.5 mL / min, and mixed in a T-shaped mixer. The mixture was reacted for 30 seconds in a PTFE tube to perform a deprotection reaction of the Fmoc group (N-terminal deprotection step). From the C-terminal activation step to the N-terminal deprotection step, the temperature was 40°C. The reaction solution in the N-terminal deprotection step was quenched with an aqueous sulfuric acid solution, washed with an aqueous sodium carbonate solution, and the organic phase was collected (extraction step). The collected organic phase was dried over sodium sulfate, and the solvent was removed by distillation to obtain 0.8095 g of H-Phe-Arg(Pbf)-O-TIPS2 (yield: quantitative, m / z=1350).
[0112] [II-4: Synthesis of H-Ser(tBu)-Phe-Arg(Pbf)-O-TIPS2 (Example 3)] (1) Synthesis of H-Phe-Arg(Pbf)-O-TIPS2 Using the manufacturing apparatus 1, a synthesis reaction was carried out in the same manner as described above, except that in the procedure described in II-3, the reaction time of the N-terminal deprotection step was changed to 10 seconds and the reaction temperature from the C-terminal activation step to the N-terminal deprotection step was changed to 60°C, and 3.2491 g of H-Phe-Arg(Pbf)-O-TIPS2 was obtained (yield: quantitative).
[0113] (2) Synthesis of H-Ser(tBu)-Phe-Arg(Pbf)-O-TIPS2 Solution 1 (DMF solution containing 0.433 mol / L of Fmoc-Ser(tBu)-OH, 0.043 mol / L of DMBA, and 0.433 mol / L of DIEA) was delivered at a flow rate of 1.2 mL / min, and solution 2 (CPME solution containing 0.255 mol / L of IBCF) was delivered at a flow rate of 2.0 mL / min, mixed in a T-shaped mixer, and reacted for 5 seconds in a PTFE tube to produce a C-terminal activated derivative of the N-terminal protected amino acid (C-terminal activation step). Next, the solution containing the C-terminal activated derivative was fed at a flow rate of 3.2 mL / min, and solution 3 (a mixed solution of DMF and CPME containing 0.200 mol / L of H-Phe-Arg(Pbf)-O-TIPS2 synthesized by the procedure described in (1)) was fed at a flow rate of 2.0 mL / min, mixed in a T-shaped mixer, and reacted for 30 seconds in a PTFE tube to perform a condensation reaction (condensation step). Next, this condensation reaction solution was fed at a flow rate of 5.2 mL / min, and solution 4 (a DMSO solution containing 1.04 mol / L of AEE) was fed at a flow rate of 0.5 mL / min, mixed in a T-shaped mixer, and reacted for 30 seconds in a PTFE tube to perform a capping reaction (capping step). Next, this capping reaction solution was fed at a flow rate of 5.7 mL / min, and solution 5 (DMSO solution containing 0.81 mol / L of 3-MPSNa) was fed at a flow rate of 1.2 mL / min, and mixed in a T-shaped mixer. Then, this mixture was fed at a flow rate of 6.9 mL / min, and solution 6 (DMSO solution containing 4.86 mol / L of DBU) was fed at a flow rate of 0.5 mL / min, and mixed in a T-shaped mixer. The mixture was reacted for 30 seconds in a PTFE tube to perform a deprotection reaction of the Fmoc group (N-terminal deprotection step). The C-terminal activation step to the N-terminal deprotection step were performed at 60 ° C. The reaction solution in the N-terminal deprotection step was quenched with an aqueous sulfuric acid solution, washed with an aqueous sodium carbonate solution, and the organic phase was collected (extraction step). The collected organic phase was dried with sodium sulfate, and the solvent was removed by distillation to obtain H-Ser(tBu)-Phe-Arg(Pbf)-O-TIPS2. Completion of the reaction was confirmed by confirming the disappearance of the raw materials and the production of the target product using UPLC.
[0114] [II-5: Synthesis of H-Glu(OtBu)-Ala-Glu(OtBu)-Lys(Boc)-Leu-O-TIPS2 (Example 4)] (1) Synthesis of H-Glu(OtBu)-Lys(Boc)-Leu-O-TIPS2 The following reaction was carried out using the production apparatus 1. Solution 1 (DMF solution containing 0.433 mol / L of Fmoc-Glu(OtBu)-OH, 0.043 mol / L of DMBA, and 0.433 mol / L of DIEA) was delivered at a flow rate of 1.2 mL / min, and solution 2 (CPME solution containing 0.255 mol / L of IBCF) was delivered at a flow rate of 2.0 mL / min, mixed in a T-shaped mixer, and reacted for 5 seconds in a PTFE tube to produce a C-terminal activated derivative of the N-terminal protected amino acid (C-terminal activation step). Next, a solution containing 0.16 mol / L of this C-terminal activated derivative was fed at a flow rate of 3.2 mL / min, and solution 3 (a mixed solution of DMF and CPME containing 0.200 mol / L of H-Lys(Boc)-Leu-O-TIPS2) was fed at a flow rate of 2.0 mL / min, mixed in a T-shaped mixer, and reacted for 30 seconds in a PTFE tube to perform a condensation reaction (condensation step). Next, this condensation reaction solution was fed at a flow rate of 5.2 mL / min, and solution 4 (a DMSO solution containing 0.65 mol / L of AEE) was fed at a flow rate of 0.8 mL / min, mixed in a T-shaped mixer, and reacted for 30 seconds in a PTFE tube to perform a capping reaction (capping step). Next, this capping reaction solution was fed at a flow rate of 6.0 mL / min, and solution 5 (DMSO solution containing 0.46 mol / L of 3-MPSNa and 1.16 mol / L of DBU) was fed at a flow rate of 2.1 mL / min, mixed in a T-shaped mixer, and reacted in a PTFE tube for 30 seconds to perform a deprotection reaction of the Fmoc group (N-terminal deprotection step). The C-terminal activation step to the N-terminal deprotection step were performed at 40°C. The reaction solution in the N-terminal deprotection step was quenched with an aqueous sulfuric acid solution, washed with an aqueous sodium carbonate solution, and the organic phase was recovered (extraction step). The recovered organic phase was dried with sodium sulfate, and the solvent was distilled off to obtain H-Glu(OtBu)-Lys(Boc)-Leu-O-TIPS2 (yield: quantitative, m / z = 1320).
[0115] (2) Synthesis of H-Ala-Glu(OtBu)-Lys(Boc)-Leu-O-TIPS2 In the procedure described in II-5(1), the amino acid contained in solution 1 was changed to Fmoc-Ala-OH, and the peptide contained in solution 3 was changed to H-Glu(OtBu)-Lys(Boc)-Leu-O-TIPS2 obtained by the synthesis described in II-5(1), but the synthesis reaction was performed in the same manner as above to obtain H-Ala-Glu(OtBu)-Lys(Boc)-Leu-O-TIPS2 (yield: 95%, m / z = 1391).
[0116] (3) Synthesis of H-Glu(OtBu)-Ala-Glu(OtBu)-Lys(Boc)-Leu-O-TIPS2 In the procedure described in II-5(1), the amino acid contained in solution 1 was changed to Fmoc-Glu(OtBu)-OH, and the peptide contained in solution 3 was changed to H-Ala-Glu(OtBu)-Lys(Boc)-Leu-O-TIPS2 obtained by the synthesis described in II-5(2), but the same synthesis reaction was performed as described above to obtain H-Glu(OtBu)-Ala-Glu(OtBu)-Lys(Boc)-Leu-O-TIPS2 (yield: 96%, m / z = 1576).
[0117] [II-6: Synthesis of HD-Tic-Oic-Arg(Pbf)-O-TIPS2 (Example 5)] (1) Synthesis of H-Oic-Arg(Pbf)-O-TIPS2 The following reaction was carried out using the production apparatus 2. Solution 1 (DIEA 5.882 mol / L) was delivered at a flow rate of 0.584 mL / min, and solution 2 (DMF solution containing 0.520 mol / L of Fmoc-Oic-OH) was delivered at a flow rate of 3.0 mL / min, mixed in a T-shaped mixer, and then mixed with solution 3 (DMF solution containing 1.0 mol / L of COMU) delivered at a flow rate of 1.5 mL / min in a T-shaped mixer, and then reacted for 5 seconds in a PTFE tube to generate a C-terminal activated derivative of the N-terminal protected amino acid (C-terminal activation step). Next, a solution containing 0.295 mol / L of this C-terminal activated derivative was delivered at a flow rate of 5.084 mL / min, and solution 4 (a mixed solution of DFM and MTHP containing 0.1 mmol / L of H-Arg(Pbf)-O-TIPS2) was delivered at a flow rate of 12.0 mL / min, mixed in a T-shaped mixer, and reacted for 60 seconds in a PTFE tube to perform a condensation reaction (condensation step). Next, this condensation reaction solution was delivered at a flow rate of 17.084 mL / min, and solution 5 (a DMSO solution containing 0.60 mol / L of AEE) was delivered at a flow rate of 2.4 mL / min, mixed in a T-shaped mixer, and reacted for 30 seconds in a PTFE tube to perform a capping reaction (capping step). Next, this capping reaction solution was fed at a flow rate of 19.484 mL / min, and solution 6 (DMSO solution containing 0.446 mol / L of 3-MPSNa and 1.114 mol / L of DBU) was fed at a flow rate of 6.3 mL / min, mixed in a T-shaped mixer, and reacted in a PTFE tube for 60 seconds to perform a deprotection reaction of the Fmoc group (N-terminal deprotection step). Next, this N-terminal deprotection reaction solution was fed at a flow rate of 25.785 mL / min with solution 7 (5% KHCO 3 Solution 8 (20% NaCl aqueous solution) was delivered at a flow rate of 25.8 mL / min, mixed in a Y-shaped mixer, further mixed in a PTFE tube for 1 second, and then the organic and aqueous phases were separated in a settler (extraction process 1). This organic phase was then mixed with solution 9 (20% NaCl aqueous solution) delivered at a flow rate of 12.0 mL / min in a Y-shaped mixer, further mixed in a PTFE tube for 1 second, and then the organic and aqueous phases were separated in a settler (extraction process 2). The C-terminal activation process to the N-terminal deprotection process were carried out at 40°C, and the extraction process was carried out at room temperature. The completion of the reaction was confirmed by confirming the disappearance of the raw materials and the production of the target product using UPLC.
[0118] (2) Synthesis of H-D-Tic-Oic-Arg(Pbf)-O-TIPS2 Using production apparatus 2, in the procedure described in II-6(1), the amino acid contained in solution 2 was changed to Fmoc-D-Tic-OH, and the peptide contained in solution 4 was changed to H-Oic-Arg(Pbf)-O-TIPS2 obtained by the synthesis described in II-6(1). A synthesis reaction was carried out in the same procedure as described above, and H-D-Tic-Oic-Arg(Pbf)-O-TIPS2 (yield: quantitative) was obtained. It was confirmed with a mass spectrometer that the target product was obtained.
[0119] <III: Comparison between peptide production by the method of the present invention and peptide production by the prior art method>
[0120] [III-1: Synthesis of H-Gly-Glu(OtBu)-O-TIPS2 by the method of the present invention (Example 6)] The following reaction was carried out using the production apparatus 1. Solution 1 (DMF solution containing 0.433 mol / L of Fmoc-Gly-OH, 0.043 mol / L of DMBA, and 0.433 mol / L of DIEA) was delivered at a flow rate of 1.2 mL / min, and solution 2 (CPME solution containing 0.255 mol / L of IBCF) was delivered at a flow rate of 2.0 mL / min, mixed in a T-shaped mixer, and reacted for 5 seconds in a PTFE tube to produce a C-terminal activated derivative of the N-terminal protected amino acid (C-terminal activation step). Next, a solution containing 0.16 mol / L of this C-terminal activated derivative was fed at a flow rate of 3.2 mL / min, and solution 3 (a mixed solution of DMF and CPME containing 0.200 mol / L of H-Glu(OtBu)-O-TIPS2) was fed at a flow rate of 2.0 mL / min, mixed in a T-shaped mixer, and reacted for 30 seconds in a PTFE tube to perform a condensation reaction (condensation step). Next, this condensation reaction solution was fed at a flow rate of 5.2 mL / min, and solution 4 (a DMSO solution containing 0.65 mol / L of AEE) was fed at a flow rate of 0.8 mL / min, mixed in a T-shaped mixer, and reacted for 30 seconds in a PTFE tube to perform a capping reaction (capping step). Next, this capping reaction solution was fed at a flow rate of 6.0 mL / min, and solution 5 (DMSO solution containing 0.46 mol / L of 3-MPSNa and 1.16 mol / L of DBU) was fed at a flow rate of 2.1 mL / min, mixed in a T-shaped mixer, and reacted in a PTFE tube for 30 seconds to perform a deprotection reaction of the Fmoc group (N-terminal deprotection step). The C-terminal activation step to the N-terminal deprotection step were performed at 40°C. The reaction solution in the N-terminal deprotection step was quenched with an aqueous sulfuric acid solution, washed with an aqueous sodium carbonate solution, and the organic phase was recovered (extraction step). The recovered organic phase was dried with sodium sulfate, and the solvent was removed by distillation to obtain H-Glu(OtBu)-Lys(Boc)-Leu-O-TIPS2.
[0121] [III-2: Synthesis of H-Gly-Glu(OtBu)-O-TIPS2 by the conventional method (Comparative Example 1)] As a comparative example, a peptide was synthesized in the same manner as in Example 9 described in WO 2020 / 218497.
[0122] (1) Condensation reaction and extraction after the condensation reaction A chloroform solution containing 0.06 mmol / mL of H-Glu(OtBu)-O-TIPS2 (Solution C1) and a DMF solution containing 0.21 mmol / mL of Fmoc-Gly-OH and 0.05 mmol / mL of HOBt (Solution C2) were mixed using a T-shaped mixer (Unionty SS-100-3, outer diameter 1 / 16 inch) with a syringe pump at a flow rate of 0.500 mL / min and 0.21 mL / min, respectively. A chloroform solution containing 0.32 mmol / mL of EDC·HCl (Solution C3) was mixed with the mixed solution of Solutions C1 and C2 using a T-shaped mixer (Unionty SS-100-3, outer diameter 1 / 16 inch) at a flow rate of 0.13 mL / min, and the mixture was reacted in a PFA tube (inner diameter 1.0 mm, length 10.0 m) for 9 min. Next, a 20% by mass NaCl aqueous solution (solution C4) was pumped at a flow rate of 0.56 mL / min using a syringe pump and mixed with the mixed solution of solutions C1, C2 and C3 using a T-shaped mixer (Union Tee SS-200-3, outer diameter 1 / 8 inch). The mixed solution was passed through a PFA tube (inner diameter 1.6 mm, length 5.0 m) for 7 minutes. The solution after passing was separated in a separatory funnel, and the organic phase containing Fmoc-Gly-Glu(OtBu)-O-TIPS2 was collected.
[0123] (2) Deprotection of the Fmoc group and washing of the organic phase after the deprotection reaction with an aqueous sodium carbonate solution A solution containing 0.05 mmol / mL of Fmoc-Gly-Glu(OtBu)-O-TIPS2 obtained by the procedure described in III-2(1) (Solution C1) and a DMF solution containing 0.52 mmol / mL of thiomalic acid and 1.57 mmol / mL of DBU (Solution C2) were delivered at flow rates of 0.73 mL / min and 0.35 mL / min, respectively, using a syringe pump, mixed using a T-shaped mixer (Union Tee SS-100-3, outer diameter 1 / 16 inch), and then reacted for 7 minutes in a PFA tube (inner diameter 1.0 mm, length 10.0 m). This deprotection reaction solution was mixed with 5.0 mass% Na 2 CO 3The aqueous solution (solution C3) was delivered at a flow rate of 0.80 mL / min using a syringe pump and mixed using a T-shaped mixer (Union Tee SS-100-3, outer diameter 1 / 16 inch). The mixed solution was passed through a PFA tube (inner diameter 1.6 mm, length 5.0 m) for 5 minutes. The solution after passing was separated using a separatory funnel, and the organic phase was collected.
[0124] (3) Washing the organic phase with an aqueous sodium chloride solution after washing with an aqueous sodium carbonate solution The organic phase (Solution C1) obtained by the procedure described in III-2(2) and a solution (Solution C2) in which 20.0 mass% NaCl aqueous solution and DMF were mixed in a volume ratio of 6:4 were pumped at a flow rate of 1.50 mL / min using a syringe pump, mixed using a T-shaped mixer (Union Tee SS-200-3, outer diameter 1 / 8 inch), and then passed through a PFA tube (inner diameter 1.6 mm, length 5.0 m) for 3 minutes. The solution after passing was separated in a separatory funnel, and the organic phase containing H-Gly-Glu(OtBu)-O-TIPS2 was collected.
[0125] [III-3: Comparison of reaction times between the synthesis according to the method of the present invention and the synthesis according to the conventional method] The results of comparing each reaction time in the synthesis by the method of the present invention described in III-1 (Example 5) with the synthesis by the prior art method described in III-2 (Example 9 described in WO 2020 / 218497) (Comparative Example 1) are shown in Table 1.
[0126] [Table 1]
[0127] As shown in Table 1, in the synthesis by the method of the present invention (Example 6), the time required for the condensation reaction and the time required for the deprotection reaction were both 30 seconds, whereas in the synthesis by the method of the prior art (Comparative Example 1), the time required for the condensation reaction and the time required for the deprotection reaction were both several minutes. In the case of Comparative Example 1, since extraction and separation treatments are performed between the condensation reaction and the deprotection reaction, it takes more time to carry out the entire synthesis process to obtain the target product.
[0128] The present invention is not limited to the above-described embodiments, but includes various modified examples. For example, the above-described embodiments have been described in detail to clearly explain the present invention, and the present invention is not necessarily limited to those including all of the configurations described. In addition, it is possible to add, delete, and / or replace part of the configuration of each embodiment with other configurations. [Explanation of symbols]
[0129] S1...C-terminal activation step, S2...Condensation step, S3...Capping step, S4...N-terminal deprotection step, S5...Extraction step, S6...C-terminal deprotection step, 11, 21, 31, 41a, 41b, 51, 51a, 51b...Inflow channel, 12, 22, 32, 42a, 42b, 52, 52a, 52b...Mixer, 13 , 23, 33, 43a, 43b, 53, 53a, 53b, 63...Outflow channel, 14a, 14b, 24, 34, 44a, 44b, 54, 54a, 54 b, 64...Pump, 58, 58a, 58b...Phase separation member, 59...Pressure adjustment means, 61...Circulation flow path, 81...Pressure gauge, 82...Flow meter, 83...Thermometer
Claims
1. a C-terminal activation step in which an N-terminal protected amino acid or peptide, the N-terminal amino group of which is protected by an N-terminal protecting group, and a C-terminal activating agent are introduced into a flow reactor, and the C-terminal carboxyl group of the N-terminal protected amino acid or peptide is activated in the flow reactor to form a C-terminal activated derivative of the N-terminal protected amino acid or peptide; a condensation step in which a C-terminal activated derivative of an N-terminal protected amino acid or peptide and a C-terminal protected amino acid or peptide in which the C-terminal carboxyl group is protected by a tag protecting group are introduced into a flow reactor, and the N-terminal protected amino acid or peptide is condensed to the N-terminal side of the C-terminal protected amino acid or peptide in the flow reactor to form an N-terminal and C-terminal protected peptide extended to the N-terminal side; an N-terminal deprotection step in which the N-terminal and C-terminal protected peptide extended on the N-terminal side and a deprotecting agent for the N-terminal protecting group are introduced into a flow reactor, and the N-terminal protecting group is deprotected in the flow reactor to form a C-terminal protected peptide extended on the N-terminal side; and an extraction step in which the reaction mixture containing the N-terminally extended C-terminally protected peptide is mixed with an aqueous phase to extract the N-terminally extended C-terminally protected peptide into an organic phase; A method for producing a peptide, comprising:
2. 2. The method of claim 1, wherein the C-terminal activating agent is selected from the group consisting of halogenated ethyl formates, halogenated isopropyl formates, halogenated isobutyl formates, carboxylic acid halides, phosgene and phosgene equivalents, carbodiimide-based condensing agents, phosphonium-based condensing agents, uronium-based condensing agents, haluronium-based condensing agents, imidazole-based condensing agents, triazine-based condensing agents, and condensation additives.
3. The tag protecting group is (i) Formula (I): 【Chemistry 1】 [In the formula, Ring A represents an aromatic ring; Y represents a hydroxyl group, a bromo group, or a chloro group; Ra, Rb, and Rc each independently represent an organic group having an aliphatic hydrocarbon group, a hydrogen atom, or an electron-withdrawing group, and at least one of Ra, Rb, and Rc is an organic group having an aliphatic hydrocarbon group; rings A, B, and C each independently may have an electron-withdrawing group; Here, the organic group having an aliphatic hydrocarbon group is Formula (b): 【Chemistry 2】 (In the formula, * indicates bond position; X 1 is -O-; R 1 is an aliphatic hydrocarbon group having 5 to 60 carbon atoms; m 1 is 1) A group represented by Formula (c): 【Chemistry 3】 (In the formula, * indicates bond position; X 2 , X 2 ', X 2 '' and X 2 ''' is -O-; R 2 and R 4 are each independently an aliphatic hydrocarbon group having 5 to 60 carbon atoms; R 3 is an organic group having an aliphatic hydrocarbon group having 5 to 60 carbon atoms; n 1 , n 2 , n 3 and n 4 is 1; m 2 is 1) A group represented by the formula: Formula (d): 【Chemistry 4】 (In the formula, * indicates bond position; X 8 represents -O-; m 3 is 2 or 3; n 5 is 1; n 6 is 3; X 7 is -O-; m 3 R 12 are each independently an alkyl group having 4 to 30 carbon atoms. A group represented by and the organic group having an aliphatic hydrocarbon group is present at the 2-position and / or 7-position of the fluorene compound. A fluorene compound represented by the formula: (ii) Formula (II): 【Chemistry 5】 [In the formula, Ring A represents an aromatic ring; Y represents a hydroxyl group, a bromo group, or a chloro group; n represents an integer of 1 to 19; Rc' represents a divalent organic group having an aliphatic hydrocarbon group; rings A, B, and C each independently may have one or more selected from an organic group having an aliphatic hydrocarbon group and an electron-withdrawing group; when there are multiple rings A, each ring A may be the same or different; when there are multiple Ys, each Y may be the same or different; when there are multiple Rc's, each Rc' may be the same or different; Here, the divalent organic group having an aliphatic hydrocarbon group is Formula (a): 【Chemistry 6】 (In the formula, Xa is absent or represents -O-, -S-, -NHCO-, or -CONH-; Rd represents an aliphatic hydrocarbon group having 5 or more carbon atoms; k 1 represents an integer of 1 to 10; when there are a plurality of Rd's, each Rd may be the same or different; when there are a plurality of Xa's, each Xa may be the same or different). is a group represented by The organic group having an aliphatic hydrocarbon group is Formula (b): 【Chemistry 7】 (In the formula, * indicates bond position; X 1 is -O-; R 1 is an aliphatic hydrocarbon group having 5 to 60 carbon atoms; m 1 is 1) A group represented by Formula (c): 【Chemistry 8】 (In the formula, * indicates bond position; X 2 , X 2 ', X 2 '' and X 2 ''' is -O-; R 2 and R 4 are each independently an aliphatic hydrocarbon group having 5 to 60 carbon atoms; R 3 is an organic group having an aliphatic hydrocarbon group having 5 to 60 carbon atoms; n 1 , n 2 , n 3 and n 4 is 1; m 2 is 1) A group represented by the formula: Formula (d): 【Chemistry 9】 (In the formula, * indicates bond position; X 8 represents -O-; m 3 is 2 or 3; n 5 is 1; n 6 is 3; X 7 is -O-; m 3 R 12 are each independently an alkyl group having 4 to 30 carbon atoms. A group represented by and the organic group having an aliphatic hydrocarbon group is present at the 2-position and / or 7-position of the fluorene compound. A fluorene compound represented by the formula: (iii) Formula (III): 【Chemistry 10】 [In the formula, Y represents a hydroxyl group or an -NHR group (R represents a hydrogen atom, an alkyl group, or an aralkyl group); R a teeth, Formula (a): 【Chemistry 11】 [In the formula, * indicates the bond position; m 1 represents an integer from 1 to 10; m 1 X 1 each independently represents a single bond, or -O-, -S-, -COO-, -OCONH-, -NHCO-, or -CONH-; R 1 and m 1 R 2 each independently represents a divalent aliphatic hydrocarbon group having 5 or more carbon atoms; and R 3 is a hydrogen atom, or Formula (III'): 【Chemistry 12】 (In the formula, Y represents a hydroxyl group or an -NHR group (R represents a hydrogen atom, an alkyl group, or an aralkyl group); * represents a bonding position; n R b each independently represents an alkoxy group having 1 to 6 carbon atoms, a halogen atom, or an alkyl group having 1 to 6 carbon atoms which may be substituted with one or more halogen atoms; and n represents an integer of 0 to 4. is a group represented by the formula: A group represented by the formula: Formula (b): 【Chemistry 13】 (In the formula, * indicates the bond position; m 2 represents 1 or 2; n 1 , n 2 , n 3 and n 4 each independently represents an integer of 0 to 2; m 2 X 2 , m 2 X 2 ' and m 2 X 2 " each independently represents a single bond, or -O-, -S-, -COO-, -OCONH-, -NHCO-, or -CONH-; m 2 R 4 and m 2 R 6 each independently represents an aliphatic hydrocarbon group having 5 or more carbon atoms; R 5 indicates an aliphatic hydrocarbon group having 5 or more carbon atoms. A group represented by the formula: Formula (c): 【Chemistry 14】 (In the formula, * indicates the bond position; m 3 represents an integer from 0 to 15; n 5 represents an integer from 0 to 11; n 6 represents an integer from 0 to 5; m 3 X 3 each independently represents a single bond, or represents -O-, -S-, -COO-, -OCONH-, -NHCO-, or -CONH-; and m 3 R 7 each independently represents a hydrogen atom, a methyl group, or an aliphatic hydrocarbon group having 5 or more carbon atoms. A group represented by the formula: Formula (d): 【Chemistry 15】 (In the formula, * indicates the bond position; n 7 X 4 each independently represents a single bond, -O-, -S-, -COO-, -OCONH-, -NHCO-, or -CONH-; R 8 represents a divalent aliphatic hydrocarbon group; n 7 R 9 each independently represents a monovalent aliphatic hydrocarbon group; n 7 represents an integer from 1 to 5; and Ar represents an arylene group. A group represented by wherein the total number of carbon atoms in the organic group is 30 or more; n R b each independently represents an alkoxy group having 1 to 6 carbon atoms, a halogen atom, or an alkyl group having 1 to 6 carbon atoms which may be substituted with one or more halogen atoms; and n represents an integer of 0 to 4. A benzyl compound represented by the formula: (iv) Formula (IV): 【Chemistry 16】 [In the formula, Y represents a hydroxyl group or an -NHR group (R represents a hydrogen atom, an alkyl group, or an aralkyl group); k and l each independently represent an integer of 0 to 5, provided that k+l is not 0; k R a and l R b are each independently Formula (a): 【Chemistry 17】 (In the formula, * indicates the bond position; m 1 represents an integer from 1 to 10; m 1 X 1 each independently represents absent, -O-, -S-, -COO-, -OCONH-, or -CONH-; m 1 R 1 each independently represents a divalent aliphatic hydrocarbon group having 5 or more carbon atoms. A group represented by Formula (b): 【Chemistry 18】 (In the formula, * indicates the bond position; m 2 represents an integer of 1 to 2; m 2 n 1 , n 2 , n 3 and n 4 each independently represents an integer of 0 to 2; m 2 X 2 , m 2 X 2 ',m 2 X 2 ''' and m 2 X 2 '' each independently represents absent, -O-, -S-, -COO-, -OCONH-, or -CONH-; 2 R 2 and R 4 each independently represents a hydrogen atom, a methyl group, or an aliphatic hydrocarbon group having 5 or more carbon atoms; R 3 indicates an aliphatic hydrocarbon group having 5 or more carbon atoms. A group represented by the formula: Formula (e): 【Chemistry 19】 (In the formula, * indicates the bond position; m 3 represents an integer from 0 to 15; n 5 represents an integer from 0 to 11; n 6 represents an integer from 0 to 5; X 2 is absent or represents -O-, -S-, -NHCO- or -CONH-; m 3 X 7 each independently represents absent, -O-, -S-, -COO-, -OCONH-, -NHCO- or -CONH-; m 3 R 12 each independently represents a hydrogen atom, a methyl group, or an aliphatic hydrocarbon group having 5 or more carbon atoms. A group represented by In the above, the organic group having an aliphatic hydrocarbon group having 5 or more carbon atoms is selected from the group consisting of In an organic group having k+l aliphatic hydrocarbon groups, the total number of carbon atoms in all the aliphatic hydrocarbon groups is 16 or more; ring A is R a may have further substituents in addition to the ring B; b may further have a substituent in addition to the above. A compound represented by the formula: (v) Formula (V): 【Chemistry 20】 [In the formula, k Q's each independently represent a single bond, -O-, -S-, -C(=O)O-, -C(=O)NH-, or -NH-; k R a each independently represents an organic group having at least one aliphatic hydrocarbon group having one or more branched chains, a total number of branched chains of 3 or more, and a total number of carbon atoms of 14 or more and 300 or less; k represents an integer of 1 to 4; R 1 is a hydrogen atom, or when Z is a group represented by the following formula (a), R 2 may be taken together with ring B to form a fluorene ring; ring A may be taken together with ring B to form a fluorene ring; 1 In addition to k QRa and C(X)(Y)Z, one or more substituents selected from the group consisting of a halogen atom, a C1-6 alkyl group optionally substituted by one or more halogen atoms, and a C1-6 alkoxy group optionally substituted by one or more halogen atoms; X represents a hydrogen atom or a phenyl group; Y represents a hydroxyl group or a -NHR group (R represents a hydrogen atom, an alkyl group or an aralkyl group); and Z represents a hydrogen atom or Formula (a): 【Chemistry 21】 (In the formula, * represents a bond position; m represents an integer of 0 to 4; m Qs each independently represent a single bond, -O-, -S-, -C(=O)O-, -C(=O)NH- or -NH-; m R b each independently represents an organic group having at least one aliphatic hydrocarbon group having one or more branched chains, a total number of branched chains of 3 or more, and a total number of carbon atoms of 14 or more and 300 or less; R 2 represents a hydrogen atom or R 1 may be taken together with ring A to form a fluorene ring; and ring B may be taken together with m QR b , and R 2 and optionally having one or more substituents selected from the group consisting of a halogen atom, a C1-6 alkyl group optionally substituted by one or more halogen atoms, and a C1-6 alkoxy group optionally substituted by one or more halogen atoms. A group represented by indicates; R a and R b The organic group having at least one aliphatic hydrocarbon group having one or more branched chains, a total number of branched chains of 3 or more, and a total number of carbon atoms of 14 to 300, Formula (b): 【Chemical 22】 (In the formula, * indicates the bond position with the adjacent atom; R 3 and R 4 each independently represents a hydrogen atom or a C1-4 alkyl group; X 1 represents a single bond, a C1-4 alkylene group, or an oxygen atom, provided that R 3 and R 4 are never both hydrogen atoms) is a group having three or more identical or different divalent groups represented by the following formula: A branched chain-containing aromatic compound represented by the formula: (vi) Formula (VI): 【Chemistry 23】 [In the formula, R 1 and R 5 is a hydrogen atom; R 2 , R 3 and R 4 is an alkoxy group having 8 to 30 carbon atoms; Rx is -CHO, -CH 2 OH, -CHR 6 -NHR 7 or CH 2 SH (where R 7 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, a benzyl group, or an alkoxy-substituted benzyl group; R 6 represents a hydrogen atom, a phenyl group, or an alkoxy-substituted phenyl group), which is a group that binds to a carboxyl group, an amino group, or a hydroxyl group of an amino acid, a peptide, or an amino acid amide, or to a linker. A compound represented by the formula: (vii) Formula (VII): 【Chemistry 24】 [In the formula, R 2 , R 4 and R 5 is a hydrogen atom, and R 1 and R 3 is an alkoxy group having 12 to 30 carbon atoms; RY is -CHO, -CH 2 OH, -CHR 6 -NHR 7 or CH 2 SH (where R 7 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, a benzyl group, or an alkoxy-substituted benzyl group; R 6 represents a hydrogen atom, a phenyl group, or an alkoxy-substituted phenyl group), which is a group that binds to a carboxyl group, an amino group, or a hydroxyl group of an amino acid, a peptide, or an amino acid amide, or to a linker. A compound represented by the formula: (viii) Formula (VIII): 【Chemistry 25】 [In the formula, R 1 , R 3 and R 5 is a hydrogen atom, and R 2 and R 4 is an alkoxy group having 12 to 30 carbon atoms; RZ is -CHO, -CH 2 OH, -CHR 6 -NHR 7 or CH 2 SH (where R 7 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, a benzyl group, or an alkoxy-substituted benzyl group; R 6 represents a hydrogen atom, a phenyl group, or an alkoxy-substituted phenyl group), which is a group that binds to a carboxyl group, an amino group, or a hydroxyl group of an amino acid, a peptide, or an amino acid amide, or to a linker. A compound represented by the formula: (ix) Formula (IX): 【Chemistry 26】 [In the formula, X is -CH 2 ORa (wherein Ra represents a hydrogen atom, a halogenocarbonyl group, or an active ester type protecting group), —CH 2 NHRb (wherein Rb represents a hydrogen atom, a linear or branched alkyl group having 1 to 6 carbon atoms, or an aralkyl group), a halogenomethyl group, an azidomethyl group, a formyl group, or an oxime, which is a group that binds to a carboxyl group, an amino group, or a hydroxyl group of an amino acid, a peptide, or an amino acid amide, or a linker; R 1 , R 2 , R 3 , R 4 , and R 5 At least one of the formulas: -OR 6 -Xa-A, the remaining groups being hydrogen atoms, halogen atoms, alkyl groups having 1 to 4 carbon atoms, or alkoxy groups having 1 to 4 carbon atoms; R 6 represents a linear or branched alkylene group having 1 to 16 carbon atoms, Xa represents O or CONRc (wherein Rc represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms); A represents Equations (1) to (11) 【Chemical 27】 (where R 7 , R 8 and R 9 may be the same or different and represent a linear or branched alkyl group having 1 to 6 carbon atoms or an aryl group which may have a substituent; R 10 represents a single bond or a linear or branched alkylene group having 1 to 3 carbon atoms; R 11 , R 12 and R 13 may be the same or different and represent a linear or branched alkylene group having 1 to 3 carbon atoms. represents either A compound represented by The method of claim 1, wherein the monovalent group is derived from a compound selected from the group consisting of:
4. The method according to claim 1, wherein the N-terminal protecting group is selected from the group consisting of a 9-fluorenylmethyloxycarbonyl group (Fmoc group), a tert-butoxycarbonyl group (Boc group), a benzyloxycarbonyl group (Cbz group), and an allyloxycarbonyl group (Alloc group).
5. After the condensation step, a capping step in which a reaction mixture containing an N-terminally and C-terminally protected peptide extended on the N-terminal side and a capping agent having an amino group are introduced into a flow reactor, and unreacted N-terminally protected amino acids or C-terminally activated derivatives of peptides are reacted with the capping agent in the flow reactor to inactivate the C-terminally activated derivatives; The method of claim 1, further comprising:
6. The method according to claim 5, wherein the capping agent having an amino group is a compound selected from the group consisting of 2-(2-aminoethoxyethanol) (AEE) and 2-aminoethyl hydrogen sulfate (AEHS).
7. a C-terminal activation means having a flow reactor and a raw material introduction member for introducing an N-terminal protected amino acid or peptide whose N-terminal amino group is protected by an N-terminal protecting group, and a C-terminal activating agent into the flow reactor, which activates the C-terminal carboxyl group of the N-terminal protected amino acid or peptide in the flow reactor to form a C-terminal activated derivative of the N-terminal protected amino acid or peptide; a condensation means having a flow reactor and a raw material introducing member for introducing into the flow reactor a C-terminal activated derivative of an N-terminal protected amino acid or peptide, and a C-terminal protected amino acid or peptide whose C-terminal carboxyl group is protected by a tag protecting group, the condensation means comprising: a flow reactor; and a raw material introducing member for introducing into the flow reactor a C-terminal activated derivative of an N-terminal protected amino acid or peptide, and a C-terminal protected amino acid or peptide whose C-terminal carboxyl group is protected by a tag protecting group, the N-terminal protected amino acid or peptide being condensed to the N-terminal side of the C-terminal protected amino acid or peptide in the flow reactor to form an N-terminal and C-terminal protected peptide extended to the N-terminal side; An N-terminal deprotection means having a flow reactor and a raw material introduction member for introducing an N-terminal and C-terminal protected peptide extended to the N-terminal side and a deprotecting agent for the N-terminal protecting group into the flow reactor, which deprotects the N-terminal protecting group in the flow reactor to form a C-terminal protected peptide extended to the N-terminal side. ; and an extraction means having a mixing member for mixing a reaction mixture containing a C-terminal protected peptide extended on the N-terminus side with an aqueous phase, for mixing the reaction mixture containing the C-terminal protected peptide extended on the N-terminus side with the aqueous phase, thereby extracting the C-terminal protected peptide extended on the N-terminus side into an organic phase; An apparatus for producing a peptide comprising:
8. a capping means having a flow reactor and a raw material introduction member for introducing a reaction mixture containing an N-terminal and C-terminal protected peptide extended on the N-terminal side, and a capping agent having an amino group into the flow reactor, which reacts an unreacted C-terminal activated derivative of an N-terminal protected amino acid or peptide with the capping agent in the flow reactor to inactivate the C-terminal activated derivative; The apparatus of claim 7, further comprising:
9. The apparatus according to claim 7, wherein the C-terminal activation means, the condensation means and the N-terminal deprotection means comprise two or more inlet flow paths, a mixer for mixing the reaction liquids flowing in from the two or more inlet flow paths, one or more outlet flow paths for discharging the reaction liquid mixed in the mixer, a pump for delivering raw materials, and a temperature control device for controlling the temperatures of the inlet flow paths, the outlet flow path, the mixer, and the flow paths of the pump.
10. 8. The apparatus according to claim 7, wherein the extraction means comprises two or more inflow channels, a mixer for mixing an aqueous phase and a reaction solution containing a C-terminal protected peptide extended on the N-terminus side and flowing in from the two or more inflow channels, a phase separation member for separating a mixed phase of the aqueous phase and the reaction solution containing a C-terminal protected peptide extended on the N-terminus side mixed in the mixer into an organic phase and an aqueous phase, one or more outflow channels for discharging the organic phase separated by the phase separation member, and a pump for delivering the aqueous phase.
11. The device according to claim 9, wherein at least one of the C-terminal activation means, the condensation means and the N-terminal deprotection means has at least one physical property detection member selected from the group consisting of a pressure gauge, a flow meter and a thermometer in the inflow channel and / or the outflow channel.
12. 11. The apparatus according to claim 10, wherein the extraction means has at least one physical property detection member selected from the group consisting of a pressure gauge, a flow meter, and a thermometer, in the inflow passage and / or the outflow passage.
13. The apparatus according to claim 7, wherein at least one of the C-terminal activation means, the condensation means, the N-terminal deprotection means and the extraction means has at least one compound detection member for detecting compounds contained in the raw materials and the reaction solution.
14. 14. The device of claim 13, wherein the at least one compound detection element is at least one element selected from the group consisting of an ultraviolet-visible spectroscopic detector, a photodiode array detector, a fluorescence detector, a differential refractive index detector, an electrical conductivity detector, an evaporative light scattering detector, an infrared spectrometer, a near-infrared spectrometer, a nuclear magnetic resonance device, and a mass spectrometer.
15. 14. The device according to claim 13, further comprising a compound separation member for separating a compound detected by the compound detection member, on the upstream side of the compound detection member in the flow path of the raw material, the reaction solution, etc.
16. 8. The apparatus according to claim 7, wherein at least one of the C-terminal activation means, the condensation means, the N-terminal deprotection means and the extraction means further has at least one outlet for sampling the reaction solution.
17. 8. The apparatus according to claim 7, further comprising a circulation means for circulating the C-terminal protected peptide extended on the N-terminal side obtained in the extraction means into a raw material introduction member for the condensation step.
Citation Information
Patent Citations
Method for producing amide
WO2019239880A1
Method for producing amide
WO2020175023A1
Method for producing peptide continuously
WO2020218497A1
Method for producing fmoc-protected amino group-containing compound
WO2023033015A1
Benzyl compound
WO2017038650A1
